<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Neurodegenerative <i>VPS41</i> variants inhibit HOPS function and mTORC1‐dependent TFEB/TFE3 regulation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073873780-8c2d4250-6193-4b25-bac0-b84e8649022c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013258</link>
            <description><![CDATA[<p class="para" id="N65542">Vacuolar protein sorting 41 (VPS41) is as part of the Homotypic fusion and Protein Sorting (HOPS) complex required for lysosomal fusion events and, independent of HOPS, for regulated secretion. Here, we report three patients with compound heterozygous mutations in <i>VPS41</i> (<i>VPS41<sup>S285P</sup></i> and <i>VPS41<sup>R662</sup></i>
<sup>*</sup>
<i>;</i>
<i>VPS41</i>
<sup>c.1423‐2A&gt;G</sup> and <i>VPS41<sup>R662</sup></i>
<sup>*</sup>) displaying neurodegeneration with ataxia and dystonia. Cellular consequences were investigated in patient fibroblasts and <i>VPS41</i>‐depleted HeLa cells. All mutants prevented formation of a functional HOPS complex, causing delayed lysosomal delivery of endocytic and autophagic cargo. By contrast, <i>VPS41<sup>S285P</sup></i> enabled regulated secretion. Strikingly, loss of VPS41 function caused a cytosolic redistribution of mTORC1, continuous nuclear localization of Transcription Factor E3 (TFE3), enhanced levels of LC3II, and a reduced autophagic response to nutrient starvation. Phosphorylation of mTORC1 substrates S6K1 and 4EBP1 was not affected. In a <i>C</i>. <i>elegans</i> model of Parkinson’s disease, co‐expression of <i>VPS41<sup>S285P</sup></i>/<i>VPS41<sup>R662</sup></i>
<sup>*</sup> abolished the neuroprotective function of VPS41 against α‐synuclein aggregates. We conclude that the <i>VPS41</i> variants specifically abrogate HOPS function, which interferes with the TFEB/TFE3 axis of mTORC1 signaling, and cause a neurodegenerative disease.</p><p class="para" id="N65541">Compound heterozygous mutations in <i>VPS41</i> were identified in patients with a neurodegenerative phenotype with dystonia and cerebellar atrophy. <i>VPS41</i> variants obstruct the HOPS complex, leading to decreased endocytic and autophagy cargo transfer to lysosomes and inhibition of mTORC1 signaling.<div class="section"><div class="box" id="N65549"><div class="imageVideo"><img src="/dataresources/secured/content-1766073873780-8c2d4250-6193-4b25-bac0-b84e8649022c/assets/EMMM-13-e13258-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-04-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Identification of TAPBPL as a novel negative regulator of T‐cell function]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073836202-c58c5d73-f589-4d26-8383-403919455f38/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013404</link>
            <description><![CDATA[<p class="para" id="N65542">T cell stimulatory and inhibitory molecules are critical for the regulation of immune responses. In this study, we identify a novel T cell co‐inhibitory molecule TAPBPL, whose amino acid sequence shares homology with known B7 family members. TAPBPL protein is expressed on resting and activated T cells, B cells, monocytes, and dendritic cells (DCs), as well as on some tumor tissues. The putative TAPBPL receptor is expressed on activated CD4 and CD8 T cells. A soluble recombinant human TAPBPL‐IgG Fc (hTAPBPL‐Ig) fusion protein inhibits the proliferation, activation, and cytokine production of both mouse and human T cells <i>in vitro</i>. <i>In vivo</i> administration of hTAPBPL‐Ig protein attenuates experimental autoimmune encephalomyelitis (EAE) in mice. Furthermore, an anti‐TAPBPL monoclonal antibody neutralizes the inhibitory activity of hTAPBPL‐Ig on T cells, enhances antitumor immunity, and inhibits tumor growth in animal models. Our results suggest that therapeutic intervention of the TAPBPL inhibitory pathway may represent a new strategy to modulate T cell‐mediated immunity for the treatment of cancer, infections, autoimmune diseases, and transplant rejection.</p><p class="para" id="N65541">T cells play a critical role in immune response. This study identifies a novel B7 family‐related T cell inhibitory molecule TAPBPL. Targeting the TAPBPL pathway may represent a new strategy to modulate T cell‐mediated immunity to treat autoimmune disease and cancer.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073836202-c58c5d73-f589-4d26-8383-403919455f38/assets/EMMM-13-e13404-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-05-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073827035-e0dce923-9688-4f76-af26-1adf336f8eb7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013366</link>
            <description><![CDATA[<p class="para" id="N65542">Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. <i>A‐priori</i> identification of platinum resistance is therefore crucial to improve on standard first‐line carboplatin–paclitaxel treatment. The DNA repair pathway homologous recombination (HR) repairs platinum‐induced damage, and the HR recombinase RAD51 is overexpressed in cancer. We therefore designed a REMARK‐compliant study of pre‐treatment RAD51 expression in EOC, using fluorescent quantitative immunohistochemistry (qIHC) to overcome challenges in quantitation of protein expression <i>in situ</i>. In a discovery cohort (<i>n</i> = 284), RAD51‐High tumours had shorter progression‐free and overall survival compared to RAD51‐Low cases in univariate and multivariate analyses. The association of RAD51 with relapse/survival was validated in a carboplatin monotherapy SCOTROC4 clinical trial cohort (<i>n</i> = 264) and was predominantly noted in HR‐proficient cancers (Myriad HRDscore &lt; 42). Interestingly, overexpression of RAD51 modified expression of immune‐regulatory pathways <i>in vitro</i>, while RAD51‐High tumours showed exclusion of cytotoxic T cells <i>in situ</i>. Our findings highlight RAD51 expression as a determinant of platinum resistance and suggest possible roles for therapy to overcome immune exclusion in RAD51‐High EOC. The qIHC approach is generalizable to other proteins with a continuum instead of discrete/bimodal expression.</p><p class="para" id="N65541">Quantitative immunohistochemistry (qIHC) reveals that high expression of the DNA repair protein RAD51 in epithelial ovarian cancer (EOC) is associated with early relapse after platinum chemotherapy, and also with decreased cytotoxic T‐cell infiltration into tumors.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073827035-e0dce923-9688-4f76-af26-1adf336f8eb7/assets/EMMM-13-e13366-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Antioxidant nanozyme counteracts HIV‐1 by modulating intracellular redox potential]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073816882-a72c66d1-0300-4e58-9172-697d8884ca62/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013314</link>
            <description><![CDATA[<p class="para" id="N65542">Reactive oxygen species (ROS) regulates the replication of human immunodeficiency virus (HIV‐1) during infection. However, the application of this knowledge to develop therapeutic strategies remained unsuccessful due to the harmful consequences of manipulating cellular antioxidant systems. Here, we show that vanadium pentoxide (V<sub>2</sub>O<sub>5</sub>) nanosheets functionally mimic natural glutathione peroxidase activity to mitigate ROS associated with HIV‐1 infection without adversely affecting cellular physiology. Using genetic reporters of glutathione redox potential and hydrogen peroxide, we showed that V<sub>2</sub>O<sub>5</sub> nanosheets catalyze ROS neutralization in HIV‐1‐infected cells and uniformly block viral reactivation and replication. Mechanistically, V<sub>2</sub>O<sub>5</sub> nanosheets suppressed HIV‐1 by affecting the expression of pathways coordinating redox balance, virus transactivation (<i>e.g.,</i> NF‐κB), inflammation, and apoptosis. Importantly, a combination of V<sub>2</sub>O<sub>5</sub> nanosheets with a pharmacological inhibitor of NF‐κB (BAY11‐7082) abrogated reactivation of HIV‐1. Lastly, V<sub>2</sub>O<sub>5</sub> nanosheets inhibit viral reactivation upon prostratin stimulation of latently infected CD4<sup>+</sup> T cells from HIV‐infected patients receiving suppressive antiretroviral therapy. Our data successfully revealed the usefulness of V<sub>2</sub>O<sub>5</sub> nanosheets against HIV and suggested nanozymes as future platforms to develop interventions against infectious diseases.</p><p class="para" id="N65541">This study describes a vanadium pentoxide (V<sub>2</sub>O<sub>5</sub>)‐based nanozyme that bolsters the anti‐HIV potential of immune cells and suppresses viral rebound in latently infected CD4<sup>+</sup> T cells derived from HIV subjects.<div class="section"><div class="box" id="N65552"><div class="imageVideo"><img src="/dataresources/secured/content-1766073816882-a72c66d1-0300-4e58-9172-697d8884ca62/assets/EMMM-13-e13314-g001.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-04-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Protein Kinase D2 drives chylomicron‐mediated lipid transport in the intestine and promotes obesity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073805402-01a1ce07-81b3-4f9b-874b-15688256960b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013548</link>
            <description><![CDATA[<p class="para" id="N65542">Lipids are the most energy‐dense components of the diet, and their overconsumption promotes obesity and diabetes. Dietary fat content has been linked to the lipid processing activity by the intestine and its overall capacity to absorb triglycerides (TG). However, the signaling cascades driving intestinal lipid absorption in response to elevated dietary fat are largely unknown. Here, we describe an unexpected role of the protein kinase D2 (PKD2) in lipid homeostasis. We demonstrate that PKD2 activity promotes chylomicron‐mediated TG transfer in enterocytes. PKD2 increases chylomicron size to enhance the TG secretion on the basolateral side of the mouse and human enterocytes, which is associated with decreased abundance of APOA4. PKD2 activation in intestine also correlates positively with circulating TG in obese human patients. Importantly, deletion, inactivation, or inhibition of PKD2 ameliorates high‐fat diet‐induced obesity and diabetes and improves gut microbiota profile in mice. Taken together, our findings suggest that PKD2 represents a key signaling node promoting dietary fat absorption and may serve as an attractive target for the treatment of obesity.</p><p class="para" id="N65541">We show that upon fat ingestion, Protein Kinase D2 stimulates chylomicron‐mediated triglyceride absorption in the intestine. Targeting PKD2, genetically or with small molecule inhibitors, reduces triglycerides absorption and prevents the development of obesity in mice and presumably in humans.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073805402-01a1ce07-81b3-4f9b-874b-15688256960b/assets/EMMM-13-e13548-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-05-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The immune suppressive microenvironment affects efficacy of radio‐immunotherapy in brain metastasis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073690733-8880134f-22f0-4519-8e5a-4ed5d0002b87/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013412</link>
            <description><![CDATA[<p class="para" id="N65542">The tumor microenvironment in brain metastases is characterized by high myeloid cell content associated with immune suppressive and cancer‐permissive functions. Moreover, brain metastases induce the recruitment of lymphocytes. Despite their presence, T‐cell‐directed therapies fail to elicit effective anti‐tumor immune responses. Here, we seek to evaluate the applicability of radio‐immunotherapy to modulate tumor immunity and overcome inhibitory effects that diminish anti‐cancer activity. Radiotherapy‐induced immune modulation resulted in an increase in cytotoxic T‐cell numbers and prevented the induction of lymphocyte‐mediated immune suppression. Radio‐immunotherapy led to significantly improved tumor control with prolonged median survival in experimental breast‐to‐brain metastasis. However, long‐term efficacy was not observed. Recurrent brain metastases showed accumulation of blood‐borne PD‐L1<sup>+</sup> myeloid cells after radio‐immunotherapy indicating the establishment of an immune suppressive environment to counteract re‐activated T‐cell responses. This finding was further supported by transcriptional analyses indicating a crucial role for monocyte‐derived macrophages in mediating immune suppression and regulating T‐cell function. Therefore, selective targeting of immune suppressive functions of myeloid cells is expected to be critical for improved therapeutic efficacy of radio‐immunotherapy in brain metastases.</p><p class="para" id="N65541">This preclinical study demonstrates the potential of radiotherapy to sensitize breast cancer brain metastasis to checkpoint inhibition. Myeloid cells contribute to immune suppression affecting long‐term survival and therefore represent a target for improved radio‐immunotherapy.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073690733-8880134f-22f0-4519-8e5a-4ed5d0002b87/assets/EMMM-13-e13412-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073413907-c2a963be-a36d-4a63-8c43-dfb7fec7534b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013560</link>
            <description><![CDATA[<p class="para" id="N65542">Rosacea is a chronic inflammatory skin disorder whose pathogenesis is unclear. Here, several lines of evidence were provided to demonstrate that mTORC1 signaling is hyperactivated in the skin, especially in the epidermis, of both rosacea patients and a mouse model of rosacea‐like skin inflammation. Both mTORC1 deletion in epithelium and inhibition by its specific inhibitors can block the development of rosacea‐like skin inflammation in LL37‐induced rosacea‐like mouse model. Conversely, hyperactivation of mTORC1 signaling aggravated rosacea‐like features. Mechanistically, mTORC1 regulates cathelicidin through a positive feedback loop, in which cathelicidin LL37 activates mTORC1 signaling by binding to Toll‐like receptor 2 (TLR2) and thus in turn increases the expression of cathelicidin itself in keratinocytes. Moreover, excess cathelicidin LL37 induces both NF‐κB activation and disease‐characteristic cytokine and chemokine production possibly via mTORC1 signaling. Topical application of rapamycin improved clinical symptoms in rosacea patients, suggesting mTORC1 inhibition can serve as a novel therapeutic avenue for rosacea.</p><p class="para" id="N65541">This study reveals a critical role of the positive feedback loop between mTORC1 signaling and cathelicidin in the pathogenesis of rosacea. Targeting mTORC1 may be a novel potential therapeutic strategy for rosacea treatment.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073413907-c2a963be-a36d-4a63-8c43-dfb7fec7534b/assets/EMMM-13-e13560-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Bi‐allelic VPS16 variants limit HOPS/CORVET levels and cause a mucopolysaccharidosis‐like disease]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073391536-7c391c0c-ada5-4be1-82ed-af69a0f1c6ef/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013376</link>
            <description><![CDATA[<p class="para" id="N65542">Lysosomal storage diseases, including mucopolysaccharidoses, result from genetic defects that impair lysosomal catabolism. Here, we describe two patients from two independent families presenting with progressive psychomotor regression, delayed myelination, brain atrophy, neutropenia, skeletal abnormalities, and mucopolysaccharidosis‐like dysmorphic features. Both patients were homozygous for the same intronic variant in <i>VPS16</i>, a gene encoding a subunit of the HOPS and CORVET complexes. The variant impaired normal mRNA splicing and led to an ~85% reduction in VPS16 protein levels in patient‐derived fibroblasts. Levels of other HOPS/CORVET subunits, including VPS33A, were similarly reduced, but restored upon re‐expression of VPS16. Patient‐derived fibroblasts showed defects in the uptake and endosomal trafficking of transferrin as well as accumulation of autophagosomes and lysosomal compartments. Re‐expression of VPS16 rescued the cellular phenotypes. Zebrafish with disrupted <i>vps16</i> expression showed impaired development, reduced myelination, and a similar accumulation of lysosomes and autophagosomes in the brain, particularly in glia cells. This disorder resembles previously reported patients with mutations in <i>VPS33A</i>, thus expanding the family of mucopolysaccharidosis‐like diseases that result from mutations in HOPS/CORVET subunits.</p><p class="para" id="N65541">This study describes two cases of developmental regression with features resembling mucopolysaccharidosis‐like disease, caused by a recessive intronic variant in the HOPS/CORVET subunit VPS16. The cellular consequences of the mutation are characterized in patient‐derived cells and a zebrafish model.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073391536-7c391c0c-ada5-4be1-82ed-af69a0f1c6ef/assets/EMMM-13-e13376-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-05-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeted genome editing <i>in vivo</i> corrects a <i>Dmd</i> duplication restoring wild‐type dystrophin expression]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073373591-c397bf4f-d999-4f7e-97b6-7ac79f6cf1a0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013228</link>
            <description><![CDATA[<p class="para" id="N65542">Tandem duplication mutations are increasingly found to be the direct cause of many rare heritable diseases, accounting for up to 10% of cases. Unfortunately, animal models recapitulating such mutations are scarce, limiting our ability to study them and develop genome editing therapies. Here, we describe the generation of a novel duplication mouse model, harboring a multi‐exonic tandem duplication in the <i>Dmd</i> gene which recapitulates a human mutation. Duplication correction of this mouse was achieved by implementing a single‐guide RNA (sgRNA) CRISPR/Cas9 approach. This strategy precisely removed a duplication mutation <i>in vivo</i>, restored full‐length dystrophin expression, and was accompanied by improvements in both histopathological and clinical phenotypes. We conclude that CRISPR/Cas9 represents a powerful tool to accurately model and treat tandem duplication mutations. Our findings will open new avenues of research for exploring the study and therapeutics of duplication disorders.</p><p class="para" id="N65541">Currently, no curative therapies exist for disorders caused by tandem duplication mutations. To address this critical need, CRISPR/Cas9‐mediated removal of a duplication mutation was demonstrated in‐vivo, leading to substantial improvement in disease phenotype in a tandem duplication DMD mouse model.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073373591-c397bf4f-d999-4f7e-97b6-7ac79f6cf1a0/assets/EMMM-13-e13228-g007.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Androgen receptor (AR) antagonism triggers acute succinate‐mediated adaptive responses to reactivate AR signaling]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073293985-c420e5b8-949f-4aa4-8e14-bb024c01736b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013427</link>
            <description><![CDATA[<p class="para" id="N65542">Treatment‐induced adaptive pathways converge to support androgen receptor (AR) reactivation and emergence of castration‐resistant prostate cancer (PCa) after AR pathway inhibition (ARPI). We set out to explore poorly defined acute adaptive responses that orchestrate shifts in energy metabolism after ARPI and identified rapid changes in succinate dehydrogenase (SDH), a TCA cycle enzyme with well‐known tumor suppressor activity. We show that AR directly regulates transcription of its catalytic subunits (SDHA, SDHB) via androgen response elements (AREs). ARPI acutely suppresses SDH activity, leading to accumulation of the oncometabolite, succinate. Succinate triggers calcium ions release from intracellular stores, which in turn phospho‐activates the AR‐cochaperone, Hsp27 via p‐CaMKK2/p‐AMPK/p‐p38 axis to enhance AR protein stabilization and activity. Activation of this pathway was seen in tissue microarray analysis on prostatectomy tissues and patient‐derived xenografts. This adaptive response is blocked by co‐targeting AR with Hsp27 under both <i>in vitro</i> and <i>in vivo</i> studies, sensitizing PCa cells to ARPI treatments.</p><p class="para" id="N65541">Prostate cancer becomes resistant to treatments targeting oncogenic androgen receptor (AR) via coordinated activity of multiple adaptive responses. This study defines metabolic reprogramming in response to AR pathway inhibition (ARPI) that supports AR reactivation.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073293985-c420e5b8-949f-4aa4-8e14-bb024c01736b/assets/EMMM-13-e13427-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073263892-01f2a0e5-15df-42a2-bc62-cc91e0326eef/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013466</link>
            <description><![CDATA[<p class="para" id="N65542">Most genetic alterations that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non‐genetic mechanisms that drive these processes. Here, we performed <i>in vivo</i> gain‐of‐function CRISPR screens and identified SMAD3, BIRC3, and SLC9A5 as key actors of BRAFi resistance. We show that their expression levels increase during acquisition of BRAFi resistance and remain high in persister cells and during relapse. The upregulation of the SMAD3 transcriptional activity (SMAD3‐signature) promotes a mesenchymal‐like phenotype and BRAFi resistance by acting as an upstream transcriptional regulator of potent BRAFi‐resistance genes such as EGFR and AXL. This SMAD3‐signature predicts resistance to both current melanoma therapies in different cohorts. Critically, chemical inhibition of SMAD3 may constitute amenable target for melanoma since it efficiently abrogates persister cells survival. Interestingly, decrease of SMAD3 activity can also be reached by inhibiting the Aryl hydrocarbon Receptor (AhR), another druggable transcription factor governing SMAD3 expression level. Our work highlights novel drug vulnerabilities that can be exploited to develop long‐lasting antimelanoma therapies.</p><p class="para" id="N65541">Using a CRISPR activation screening, we identified genes involved in BRAF inhibitor (BRAFi) resistance in cutaneous melanoma. Their upregulation promoted tumour growth of therapy‐naïve melanoma cells and BRAFi‐resistance. Inhibition of these genes (not mutated) may be useful for therapy.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073263892-01f2a0e5-15df-42a2-bc62-cc91e0326eef/assets/EMMM-13-e13466-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Menin‐regulated Pbk controls high fat diet‐induced compensatory beta cell proliferation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766073233169-f9d9250b-4573-43ff-b8c2-3caafb6ed3cc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013524</link>
            <description><![CDATA[<p class="para" id="N65542">Pancreatic beta cells undergo compensatory proliferation in the early phase of type 2 diabetes. While pathways such as FoxM1 are involved in regulating compensatory beta cell proliferation, given the lack of therapeutics effectively targeting beta cell proliferation, other targetable pathways need to be identified. Herein, we show that Pbk, a serine/threonine protein kinase, is essential for high fat diet (HFD)‐induced beta cell proliferation <i>in vivo</i> using a Pbk kinase deficiency knock‐in mouse model. Mechanistically, JunD recruits menin and HDAC3 complex to the <i>Pbk</i> promoter to reduce histone H3 acetylation, leading to epigenetic repression of Pbk expression. Moreover, menin inhibitor (MI) disrupts the menin–JunD interaction and augments <i>Pbk</i> transcription. Importantly, MI administration increases beta cell proliferation, ameliorating hyperglycemia, and impaired glucose tolerance (IGT) in HFD‐induced diabetic mice. Notably, Pbk is required for the MI‐induced beta cell proliferation and improvement of IGT. Together, these results demonstrate the repressive role of the menin/JunD/Pbk axis in regulating HFD‐induced compensatory beta cell proliferation and pharmacologically regulating this axis may serve as a novel strategy for type 2 diabetes therapy.</p><p class="para" id="N65541">Pancreatic beta cells undergo compensatory proliferation in the early phase of type 2 diabetes. Understanding the mechanism and regulation of compensatory beta cell proliferation may allow for improved treatment options for diabetes. Herein we elucidated that the menin/JunD/Pbk axis is important in compensatory beta‐cell proliferation.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766073233169-f9d9250b-4573-43ff-b8c2-3caafb6ed3cc/assets/EMMM-13-e13524-g007.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-04-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A weakened interface in the P182L variant of HSP27 associated with severe Charcot‐Marie‐Tooth neuropathy causes aberrant binding to interacting proteins]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766030164919-5e3892c1-20da-4a11-9ec8-05694bd748ec/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2019103811</link>
            <description><![CDATA[<p class="para" id="N65542">HSP27 is a human molecular chaperone that forms large, dynamic oligomers and functions in many aspects of cellular homeostasis. Mutations in HSP27 cause Charcot‐Marie‐Tooth (CMT) disease, the most common inherited disorder of the peripheral nervous system. A particularly severe form of CMT disease is triggered by the P182L mutation in the highly conserved IxI/V motif of the disordered C‐terminal region, which interacts weakly with the structured core domain of HSP27. Here, we observed that the P182L mutation disrupts the chaperone activity and significantly increases the size of HSP27 oligomers formed <i>in vivo</i>, including in motor neurons differentiated from CMT patient‐derived stem cells. Using NMR spectroscopy, we determined that the P182L mutation decreases the affinity of the HSP27 IxI/V motif for its own core domain, leaving this binding site more accessible for other IxI/V‐containing proteins. We identified multiple IxI/V‐bearing proteins that bind with higher affinity to the P182L variant due to the increased availability of the IxI/V‐binding site. Our results provide a mechanistic basis for the impact of the P182L mutation on HSP27 and suggest that the IxI/V motif plays an important, regulatory role in modulating protein–protein interactions.</p><p class="para" id="N65541">NMR studies define how the P182L mutation alters intramolecular interactions to increase HSP27 accessibility for numerous binding proteins, compromising its chaperone function in patient cell‐derived motor neurons.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766030164919-5e3892c1-20da-4a11-9ec8-05694bd748ec/assets/EMBJ-40-e103811-g003.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Mitochondrial translation deficiency impairs NAD<sup>+</sup>‐mediated lysosomal acidification]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766030107355-90e64c8f-950d-49ac-add4-9c2a6e04f9f3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105268</link>
            <description><![CDATA[<p class="para" id="N65542">Mitochondrial translation dysfunction is associated with neurodegenerative and cardiovascular diseases. Cells eliminate defective mitochondria by the lysosomal machinery via autophagy. The relationship between mitochondrial translation and lysosomal function is unknown. In this study, mitochondrial translation‐deficient hearts from p32‐knockout mice were found to exhibit enlarged lysosomes containing lipofuscin, suggesting impaired lysosome and autolysosome function. These mice also displayed autophagic abnormalities, such as p62 accumulation and LC3 localization around broken mitochondria. The expression of genes encoding for nicotinamide adenine dinucleotide (NAD<sup>+</sup>) biosynthetic enzymes—Nmnat3 and Nampt—and NAD<sup>+</sup> levels were decreased, suggesting that NAD<sup>+</sup> is essential for maintaining lysosomal acidification. Conversely, nicotinamide mononucleotide (NMN) administration or Nmnat3 overexpression rescued lysosomal acidification. Nmnat3 gene expression is suppressed by HIF1α, a transcription factor that is stabilized by mitochondrial translation dysfunction, suggesting that HIF1α‐Nmnat3‐mediated NAD<sup>+</sup> production is important for lysosomal function. The glycolytic enzymes GAPDH and PGK1 were found associated with lysosomal vesicles, and NAD<sup>+</sup> was required for ATP production around lysosomal vesicles. Thus, we conclude that NAD<sup>+</sup> content affected by mitochondrial dysfunction is essential for lysosomal maintenance.</p><p class="para" id="N65541">Mitochondrial dysfunction leads to decreased HIF1α‐Nmnat3‐dependent NAD<sup>+</sup> production, inhibiting localized ATP production at the lysosomal membranes and vATPase function in mouse heart.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1766030107355-90e64c8f-950d-49ac-add4-9c2a6e04f9f3/assets/EMBJ-40-e105268-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Cryo‐EM reveals the complex architecture of dynactin's shoulder region and pointed end]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766030058871-0473c3a0-02e5-4177-b553-18cdd6ad2823/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020106164</link>
            <description><![CDATA[<p class="para" id="N65542">Dynactin is a 1.1 MDa complex that activates the molecular motor dynein for ultra‐processive transport along microtubules. In order to do this, it forms a tripartite complex with dynein and a coiled‐coil adaptor. Dynactin consists of an actin‐related filament whose length is defined by its flexible shoulder domain. Despite previous cryo‐EM structures, the molecular architecture of the shoulder and pointed end of the filament is still poorly understood due to the lack of high‐resolution information in these regions. Here we combine multiple cryo‐EM datasets and define precise masking strategies for particle signal subtraction and 3D classification. This overcomes domain flexibility and results in high‐resolution maps into which we can build the shoulder and pointed end. The unique architecture of the shoulder securely houses the p150 subunit and positions the four identical p50 subunits in different conformations to bind dynactin’s filament. The pointed end map allows us to build the first structure of p62 and reveals the molecular basis for cargo adaptor binding to different sites at the pointed end.</p><p class="para" id="N65541">Refinement of dynactin cryo‐EM structures offers insights into dynactin subunit organization in the shoulder region and adaptor binding to its pointed end.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766030058871-0473c3a0-02e5-4177-b553-18cdd6ad2823/assets/EMBJ-40-e106164-g007.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Unbiased proteomic profiling of host cell extracellular vesicle composition and dynamics upon HIV‐1 infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766029916136-4bf0d689-5b1f-4915-8d23-5eb8562313e7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105492</link>
            <description><![CDATA[<p class="para" id="N65542">Cells release diverse types of extracellular vesicles (EVs), which transfer complex signals to surrounding cells. Specific markers to distinguish different EVs (e.g. exosomes, ectosomes, enveloped viruses like HIV) are still lacking. We have developed a proteomic profiling approach for characterizing EV subtype composition and applied it to human Jurkat T cells. We generated an interactive database to define groups of proteins with similar profiles, suggesting release in similar EVs. Biochemical validation confirmed the presence of preferred partners of commonly used exosome markers in EVs: CD81/ADAM10/ITGB1, and CD63/syntenin. We then compared EVs from control and HIV‐1‐infected cells. HIV infection altered EV profiles of several cellular proteins, including MOV10 and SPN, which became incorporated into HIV virions, and SERINC3, which was re‐routed to non‐viral EVs in a Nef‐dependent manner. Furthermore, we found that SERINC3 controls the surface composition of EVs. Our workflow provides an unbiased approach for identifying candidate markers and potential regulators of EV subtypes. It can be widely applied to <i>in vitro</i> experimental systems for investigating physiological or pathological modifications of EV release.</p><p class="para" id="N65541">A new proteomic approach allows comprehensive characterisation of exosome heterogeneity in human T cells.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766029916136-4bf0d689-5b1f-4915-8d23-5eb8562313e7/assets/EMBJ-40-e105492-g005.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[PIF1 helicase promotes break‐induced replication in mammalian cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766029898752-9f558dd0-7bfc-4806-819f-790a63922417/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104509</link>
            <description><![CDATA[<p class="para" id="N65542">Break‐induced replication (BIR) is a specialized homologous‐recombination pathway for DNA double‐strand break (DSB) repair, which often induces genome instability. In this study, we establish EGFP‐based recombination reporters to systematically study BIR in mammalian cells and demonstrate an important role of human PIF1 helicase in promoting BIR. We show that at endonuclease cleavage sites, PIF1‐dependent BIR is used for homology‐initiated recombination requiring long track DNA synthesis, but not short track gene conversion (STGC). We also show that structure formation‐prone AT‐rich DNA sequences derived from common fragile sites (CFS‐ATs) induce BIR upon replication stress and oncogenic stress, and PCNA‐dependent loading of PIF1 onto collapsed/broken forks is critical for BIR activation. At broken replication forks, even STGC‐mediated repair of double‐ended DSBs depends on POLD3 and PIF1, revealing an unexpected mechanism of BIR activation upon replication stress that differs from the conventional BIR activation model requiring DSB end sensing at endonuclease‐generated breaks. Furthermore, loss of PIF1 is synthetically lethal with loss of FANCM, which is involved in protecting CFS‐ATs. The breast cancer‐associated PIF1 mutant L319P is defective in BIR, suggesting a direct link of BIR to oncogenic processes.</p><p class="para" id="N65541">BIR‐mediated homologous recombination allows mammalian cells to cope with replication stress and is differently controlled at fork‐breakage‐induced vs endonucleases‐generated DSBs.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766029898752-9f558dd0-7bfc-4806-819f-790a63922417/assets/EMBJ-40-e104509-g003.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Psoriatic skin inflammation is promoted by c‐Jun/AP‐1‐dependent CCL2 and IL‐23 expression in dendritic cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766010902777-9f88c139-6508-4194-a1dd-67c8af445bad/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012409</link>
            <description><![CDATA[<p class="para" id="N65542">Toll‐like receptor (TLR) stimulation induces innate immune responses involved in many inflammatory disorders including psoriasis. Although activation of the AP‐1 transcription factor complex is common in TLR signaling, the specific involvement and induced targets remain poorly understood. Here, we investigated the role of c‐Jun/AP‐1 protein in skin inflammation following TLR7 activation using human psoriatic skin, dendritic cells (DC), and genetically engineered mouse models. We show that c‐Jun regulates CCL2 production in DCs leading to impaired recruitment of plasmacytoid DCs to inflamed skin after treatment with the TLR7/8 agonist Imiquimod. Furthermore, deletion of c‐Jun in DCs or chemical blockade of JNK/c‐Jun signaling ameliorates psoriasis‐like skin inflammation by reducing IL‐23 production in DCs. Importantly, the control of IL‐23 and CCL2 by c‐Jun is most pronounced in murine type‐2 DCs. CCL2 and IL‐23 expression co‐localize with c‐Jun in type‐2/inflammatory DCs in human psoriatic skin and JNK‐AP‐1 inhibition reduces the expression of these targets in TLR7/8‐stimulated human DCs. Therefore, c‐Jun/AP‐1 is a central driver of TLR7‐induced immune responses by DCs and JNK/c‐Jun a potential therapeutic target in psoriasis.</p><p class="para" id="N65541">Based on genetically engineered mouse models (GEMMs) and human psoriasis biopsies, this study suggests that c‐Jun in Dendritic Cells (DC) contributes to psoriasis by controlling CCL2 and IL‐23 production, and further identifies the JNK/c‐Jun axis as a druggable target.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766010902777-9f88c139-6508-4194-a1dd-67c8af445bad/assets/EMMM-13-e12409-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeting netrin‐3 in small cell lung cancer and neuroblastoma]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009899041-7da7b950-8598-44e7-a53b-1d4c955396a7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012878</link>
            <description><![CDATA[<p class="para" id="N65542">The navigation cue netrin‐1 is well‐documented for its key role in cancer development and represents a promising therapeutic target currently under clinical investigation. Phase 1 and 2 clinical trials are ongoing with NP137, a humanized monoclonal antibody against netrin‐1. Interestingly, the epitope recognized by NP137 in netrin‐1 shares 90% homology with its counterpart in netrin‐3, the closest member to netrin‐1 in humans, for which little is known in the field of cancer. Here, we unveiled that netrin‐3 appears to be expressed specifically in human neuroblastoma (NB) and small cell lung cancer (SCLC), two subtypes of neuroectodermal/neuroendocrine lineages. Netrin‐3 and netrin‐1 expression are mutually exclusive, and the former is driven by the MYCN oncogene in NB, and the ASCL‐1 or NeuroD1 transcription factors in SCLC. Netrin‐3 expression is correlated with disease stage, aggressiveness, and overall survival in NB. Mechanistically, we confirmed the high affinity of netrin‐3 for netrin‐1 receptors and we demonstrated that netrin‐3 genetic silencing or interference using NP137, delayed tumor engraftment, and reduced tumor growth in animal models. Altogether, these data support the targeting of netrin‐3 in NB and SCLC.</p><p class="para" id="N65541">Expression and function of netrin‐3 have so far never been investigated in human cancers. Based on cohort analyses, this study shows that netrin‐3 is a putative therapeutic target in both small cell lung cancer (SCLC) and neuroblastoma (NB).<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009899041-7da7b950-8598-44e7-a53b-1d4c955396a7/assets/EMMM-13-e12878-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[WNT inhibition creates a BRCA‐like state in Wnt‐addicted cancer]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009887437-a4f53f35-ad69-4a04-b009-f4b154a5646d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013349</link>
            <description><![CDATA[<p class="para" id="N65542">Wnt signaling maintains diverse adult stem cell compartments and is implicated in chemotherapy resistance in cancer. PORCN inhibitors that block Wnt secretion have proven effective in Wnt‐addicted preclinical cancer models and are in clinical trials. In a survey for potential combination therapies, we found that Wnt inhibition synergizes with the PARP inhibitor olaparib in Wnt‐addicted cancers. Mechanistically, we find that multiple genes in the homologous recombination and Fanconi anemia repair pathways, including <i>BRCA1</i>, <i>FANCD2</i>, and <i>RAD51</i>, are dependent on Wnt/β‐catenin signaling in Wnt‐high cancers, and treatment with a PORCN inhibitor creates a BRCA‐like state. This coherent regulation of DNA repair genes occurs in part via a Wnt/β‐catenin/MYBL2 axis. Importantly, this pathway also functions in intestinal crypts, where high expression of BRCA and Fanconi anemia genes is seen in intestinal stem cells, with further upregulation in Wnt‐high APC<sup>min</sup> mutant polyps. Our findings suggest a general paradigm that Wnt/β‐catenin signaling enhances DNA repair in stem cells and cancers to maintain genomic integrity. Conversely, interventions that block Wnt signaling may sensitize cancers to radiation and other DNA damaging agents.</p><p class="para" id="N65541">This study identifies that Wnt/β‐catenin signaling regulates homologous recombination and Fanconi anaemia DNA repair pathways in Wnt‐high cancers and intestinal stem cells. Wnt signaling inhibition induces a BRCA‐like state; and Wnt and PARP inhibitors synergize to inhibit Wnt‐addicted cancers.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009887437-a4f53f35-ad69-4a04-b009-f4b154a5646d/assets/EMMM-13-e13349-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The enhancement of activity rescues the establishment of <i>Mecp2</i> null neuronal phenotypes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009854512-9e3c6539-a110-45ed-aa80-a44157389021/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012433</link>
            <description><![CDATA[<p class="para" id="N65542">
<i>MECP2</i> mutations cause Rett syndrome (RTT), a severe and progressive neurodevelopmental disorder mainly affecting females. Although RTT patients exhibit delayed onset of symptoms, several evidences demonstrate that MeCP2 deficiency alters early development of the brain. Indeed, during early maturation, <i>Mecp2</i> null cortical neurons display widespread transcriptional changes, reduced activity, and defective morphology. It has been proposed that during brain development these elements are linked in a feed‐forward cycle where neuronal activity drives transcriptional and morphological changes that further increase network maturity. We hypothesized that the enhancement of neuronal activity during early maturation might prevent the onset of RTT‐typical molecular and cellular phenotypes. Accordingly, we show that the enhancement of excitability, obtained by adding to neuronal cultures Ampakine CX546, rescues transcription of several genes, neuronal morphology, and responsiveness to <i>stimuli</i>. Greater effects are achieved in response to earlier treatments. <i>In vivo</i>, short and early administration of CX546 to <i>Mecp2</i> null mice prolongs lifespan, delays the disease progression, and rescues motor abilities and spatial memory, thus confirming the value for RTT of an early restoration of neuronal activity.</p><p class="para" id="N65541">Neuronal activity drives transcriptional and morphological changes that ensure maturation. Such mechanism is affected by Mecp2 absence. We show the rescue effects produced by enhancing <i>Mecp2</i> null neurons activity and propose new therapeutic time windows for the treatment of Rett syndrome.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1766009854512-9e3c6539-a110-45ed-aa80-a44157389021/assets/EMMM-13-e12433-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009817242-274d34a1-8eb4-44c3-93af-88c5bb68b37d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013392</link>
            <description><![CDATA[<p class="para" id="N65542">Gene therapy using recombinant adeno‐associated virus (rAAV) vectors to treat blinding retinal dystrophies has become clinical reality. Therapeutically impactful targeting of photoreceptors still relies on subretinal vector delivery, which detaches the retina and harbours substantial risks of collateral damage, often without achieving widespread photoreceptor transduction. Herein, we report the development of novel engineered rAAV vectors that enable efficient targeting of photoreceptors via less invasive intravitreal administration. A unique <i>in vivo</i> selection procedure was performed, where an AAV2‐based peptide‐display library was intravenously administered in mice, followed by isolation of vector DNA from target cells after only 24 h. This stringent selection yielded novel vectors, termed AAV2.GL and AAV2.NN, which mediate widespread and high‐level retinal transduction after intravitreal injection in mice, dogs and non‐human primates. Importantly, both vectors efficiently transduce photoreceptors in human retinal explant cultures. As proof‐of‐concept, intravitreal <i>Cnga3</i> delivery using AAV2.GL lead to cone‐specific expression of Cnga3 protein and rescued photopic cone responses in the <i>Cnga3</i>
<sup>−/−</sup> mouse model of achromatopsia. These novel rAAV vectors expand the clinical applicability of gene therapy for blinding human retinal dystrophies.</p><p class="para" id="N65541">Ocular gene therapy aims to improve or preserve vision in patients with inherited blinding disorders. The current technology still relies on subretinal administration of therapeutic vectors, which harbours risks of collateral damage and only treats a small portion of the affected retina. This study presents two novel engineered viral vectors capable of widespread targeting of retinal cells through a less invasive delivery route.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009817242-274d34a1-8eb4-44c3-93af-88c5bb68b37d/assets/EMMM-13-e13392-g003.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009789134-4e0b1cf5-8016-4547-9986-986da8ec5279/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013144</link>
            <description><![CDATA[<p class="para" id="N65542">Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistance to the first‐, second‐, and third‐generation drugs. To explore alternatives to such whack‐a‐mole strategies, we simulated in patient‐derived xenograft models the situation of patients receiving first‐line TKIs. Monotherapies comprising approved first‐line TKIs were compared to combinations with antibodies specific to EGFR and HER2. We observed uniform and strong superiority of all drug combinations over the respective monotherapies. Prolonged treatments, high TKI dose, and specificity were essential for drug–drug cooperation. Blocking pathways essential for mitosis (e.g., FOXM1), along with downregulation of resistance‐conferring receptors (e.g., AXL), might underlie drug cooperation. Thus, upfront treatments using combinations of TKIs and antibodies can prevent emergence of resistance and hence might replace the widely applied sequential treatments utilizing next‐generation TKIs.</p><p class="para" id="N65541">Simulation in patient‐derived xenografts of the situation of patients with lung cancer, who receive first‐line EGFR kinase inhibitors, revealed that monoclonal antibodies can prevent emergence of resistance to the currently approved inhibitors.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009789134-4e0b1cf5-8016-4547-9986-986da8ec5279/assets/EMMM-13-e13144-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Cooperation of LIM domain‐binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009765504-f57717f8-79b1-4af9-b88c-d6c985bdb0f6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012574</link>
            <description><![CDATA[<p class="para" id="N65542">Genomic defects with large effect size can help elucidate unknown pathologic architecture of mental disorders. We previously reported on a patient with schizophrenia and a balanced translocation between chromosomes 4 and 13 and found that the breakpoint within chromosome 4 is located near the <i>LDB2</i> gene. We show here that <i>Ldb2</i> knockout (KO) mice displayed multiple deficits relevant to mental disorders. In particular, <i>Ldb2</i> KO mice exhibited deficits in the fear‐conditioning paradigm. Analysis of the amygdala suggested that dysregulation of synaptic activities controlled by the immediate early gene <i>Arc</i> is involved in the phenotypes. We show that LDB2 forms protein complexes with known transcription factors. Consistently, ChIP‐seq analyses indicated that LDB2 binds to &gt; 10,000 genomic sites in human neurospheres. We found that many of those sites, including the promoter region of <i>ARC</i>, are occupied by EGR transcription factors. Our previous study showed an association of the <i>EGR</i> family genes with schizophrenia. Collectively, the findings suggest that dysregulation in the gene expression controlled by the LDB2‐EGR axis underlies a pathogenesis of subset of mental disorders.</p><p class="para" id="N65541">The <i>LDB2</i> gene is mapped at the breakpoint of a balanced chromosomal translocation seen in a patient with schizophrenia. This study investigates the role of LDB2 and transcriptional regulation exerted by the “LDB2‐EGR axis” in the pathogenesis of mental disorders.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1766009765504-f57717f8-79b1-4af9-b88c-d6c985bdb0f6/assets/EMMM-13-e12574-g012.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009721416-a948896e-a8ce-4cf9-94c8-cb3aa8e64c43/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013328</link>
            <description><![CDATA[<p class="para" id="N65542">DMD is a rare disorder characterized by progressive muscle degeneration and premature death. Therapy development is delayed by difficulties to monitor efficacy non‐invasively in clinical trials. In this study, we used RNA‐sequencing to describe the pathophysiological changes in skeletal muscle of 3 dystrophic mouse models. We show how dystrophic changes in muscle are reflected in blood by analyzing paired muscle and blood samples. Analysis of repeated blood measurements followed the dystrophic signature at five equally spaced time points over a period of seven months. Treatment with two antisense drugs harboring different levels of dystrophin recovery identified genes associated with safety and efficacy. Evaluation of the blood gene expression in a cohort of DMD patients enabled the comparison between preclinical models and patients, and the identification of genes associated with physical performance, treatment with corticosteroids and body measures. The presented results provide evidence that blood RNA‐sequencing can serve as a tool to evaluate disease progression in dystrophic mice and patients, as well as to monitor response to (dystrophin‐restoring) therapies in preclinical drug development and in clinical trials.</p><p class="para" id="N65541">This study explored the potential of RNA‐sequencing of peripheral blood to track non‐invasively disease progression and response to treatment in dystrophic mice and in patients affected by Duchenne Muscular Dystrophy (DMD).<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009721416-a948896e-a8ce-4cf9-94c8-cb3aa8e64c43/assets/EMMM-13-e13328-g004.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009623676-36a4b67a-e4e2-4963-9180-d51d9623613a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012871</link>
            <description><![CDATA[<p class="para" id="N65542">The correspondence of cell state changes in diseased organs to peripheral protein signatures is currently unknown. Here, we generated and integrated single‐cell transcriptomic and proteomic data from multiple large pulmonary fibrosis patient cohorts. Integration of 233,638 single‐cell transcriptomes (<i>n</i> = 61) across three independent cohorts enabled us to derive shifts in cell type proportions and a robust core set of genes altered in lung fibrosis for 45 cell types. Mass spectrometry analysis of lung lavage fluid (<i>n</i> = 124) and plasma (<i>n</i> = 141) proteomes identified distinct protein signatures correlated with diagnosis, lung function, and injury status. A novel SSTR2+ pericyte state correlated with disease severity and was reflected in lavage fluid by increased levels of the complement regulatory factor CFHR1. We further discovered CRTAC1 as a biomarker of alveolar type‐2 epithelial cell health status in lavage fluid and plasma. Using cross‐modal analysis and machine learning, we identified the cellular source of biomarkers and demonstrated that information transfer between modalities correctly predicts disease status, suggesting feasibility of clinical cell state monitoring through longitudinal sampling of body fluid proteomes.</p><p class="para" id="N65541">Multi‐modal integration of single‐cell RNA‐seq data from lung tissue and proteomic data from body fluids across independent lung fibrosis patient cohorts revealed biomarker signatures that correspond with cell state changes during disease progression.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009623676-36a4b67a-e4e2-4963-9180-d51d9623613a/assets/EMMM-13-e12871-g005.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The NFIB‐ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009560548-d0161e79-7f31-46b5-987a-9f8f014eb669/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013162</link>
            <description><![CDATA[<p class="para" id="N65542">Metastasis is the main cause of deaths related to solid cancers. Active transcriptional programmes are known to regulate the metastatic cascade but the molecular determinants of metastatic colonization remain elusive. Using an inducible <i>piggyBac</i> (PB) transposon mutagenesis screen, we have shown that overexpression of the transcription factor nuclear factor IB (NFIB) alone is sufficient to enhance primary mammary tumour growth and lung metastatic colonization. Mechanistically and functionally, NFIB directly increases expression of the oxidoreductase <i>ERO1A</i>, which enhances HIF1α‐VEGFA‐mediated angiogenesis and colonization, the last and fatal step of the metastatic cascade. <i>NFIB</i> is thus clinically relevant: it is preferentially expressed in the poor‐prognostic group of basal‐like breast cancers, and high expression of the <i>NFIB/ERO1A/VEGFA</i> pathway correlates with reduced breast cancer patient survival.</p><p class="para" id="N65541">Transcriptional factor nuclear factor IB (NFIB) is sufficient to enhance lung metastatic colonization via enhanced angiogenesis, thus revealing a targetable network that promotes breast cancer colonization.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009560548-d0161e79-7f31-46b5-987a-9f8f014eb669/assets/EMMM-13-e13162-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009440692-2330dc23-eae3-4592-9dc2-d948c2bd7ba4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012461</link>
            <description><![CDATA[<p class="para" id="N65542">By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi‐agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high‐throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation‐like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard‐of‐care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.</p><p class="para" id="N65541">This study identifies novel combinatorial drug treatments to induce death of different tumor cells, and defines the mechanisms of synergism between a mitochondrial uncoupler and antidepressants or dopamine receptor antagonists.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009440692-2330dc23-eae3-4592-9dc2-d948c2bd7ba4/assets/EMMM-13-e12461-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Comparative intravital imaging of human and rodent malaria sporozoites reveals the skin is not a species‐specific barrier]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009290759-491ded8e-c1c1-496e-8112-a619dbe51946/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.201911796</link>
            <description><![CDATA[<p class="para" id="N65542">Malaria infection starts with the injection of <i>Plasmodium</i> sporozoites into the host’s skin. Sporozoites are motile and move in the skin to find and enter blood vessels to be carried to the liver. Here, we present the first characterization of <i>P. falciparum</i> sporozoites <i>in vivo</i>, analyzing their motility in mouse skin and human skin xenografts and comparing their motility to two rodent malaria species. These data suggest that in contrast to the liver and blood stages, the skin is not a species‐specific barrier for <i>Plasmodium</i>. Indeed, <i>P. falciparum</i> sporozoites enter blood vessels in mouse skin at similar rates to the rodent malaria parasites. Furthermore, we demonstrate that antibodies targeting sporozoites significantly impact the motility of <i>P. falciparum</i> sporozoites in mouse skin. Though the sporozoite stage is a validated vaccine target, vaccine trials have been hampered by the lack of good animal models for human malaria parasites. Pre‐clinical screening of next‐generation vaccines would be significantly aided by the <i>in vivo</i> platform we describe here, expediting down‐selection of candidates prior to human vaccine trials.</p><p class="para" id="N65541">We show that human and rodent malaria sporozoites move and enter blood vessels with similar efficiency in mouse skin. Our data demonstrate that intravital imaging of <i>P. falciparum</i> sporozoites at the dermal inoculation site can be used to assess the impact of antibody on sporozoite migration.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1766009290759-491ded8e-c1c1-496e-8112-a619dbe51946/assets/EMMM-13-e11796-g002.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009280123-e1f8bc6b-2d21-4b47-8155-4c7e11b9ae3d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013390</link>
            <description><![CDATA[<p class="para" id="N65542">Immunogenicity is considered one important criterion for progression of candidate vaccines to further clinical evaluation. We tested this assumption in an infection and vaccination model for malaria pre‐erythrocytic stages. We engineered <i>Plasmodium berghei</i> parasites that harbour a well‐characterised epitope for stimulation of CD8<sup>+</sup> T cells, either as an antigen in the sporozoite surface‐expressed circumsporozoite protein or the parasitophorous vacuole membrane associated protein upregulated in sporozoites 4 (UIS4) expressed in exo‐erythrocytic forms (EEFs). We show that the antigen origin results in profound differences in immunogenicity with a sporozoite antigen eliciting robust, superior antigen‐specific CD8<sup>+</sup> T‐cell responses, whilst an EEF antigen evokes poor responses. Despite their contrasting immunogenic properties, both sporozoite and EEF antigens gain access to antigen presentation pathways in hepatocytes, as recognition and targeting by vaccine‐induced effector CD8<sup>+</sup> T cells results in high levels of protection when targeting either antigen. Our study is the first demonstration that poorly immunogenic EEF antigens do not preclude their susceptibility to antigen‐specific CD8<sup>+</sup> T‐cell killing, which has wide‐ranging implications on antigen prioritisation for next‐generation pre‐erythrocytic malaria vaccines.</p><p class="para" id="N65541">Key benchmarks for malaria vaccine design were investigated. Antigen immunogenicity and accessibility were studied with results indicating the proof‐of‐concept that a poorly immunogenic exo‐erythrocytic form (EEF) antigen is comparably vulnerable as a strongly immunogenic sporozoite antigen to targeting by vaccine‐induced effector CD8<sup>+</sup> T cells.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1766009280123-e1f8bc6b-2d21-4b47-8155-4c7e11b9ae3d/assets/EMMM-13-e13390-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009227970-48f21351-e505-4f8c-b695-4353b09141f2/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013076</link>
            <description><![CDATA[<p class="para" id="N65542">Astrocytes and microglia are brain‐resident glia that can establish harmful inflammatory environments in disease contexts and thereby contribute to the progression of neuronal loss in neurodegenerative disorders. Correcting the diseased properties of glia is therefore an appealing strategy for treating brain diseases. Previous studies have shown that serum/ glucocorticoid related kinase 1 (SGK1) is upregulated in the brains of patients with various neurodegenerative disorders, suggesting its involvement in the pathogenesis of those diseases. In this study, we show that inhibiting glial SGK1 corrects the pro‐inflammatory properties of glia by suppressing the intracellular NFκB‐, NLRP3‐inflammasome‐, and CGAS‐STING‐mediated inflammatory pathways. Furthermore, SGK1 inhibition potentiated glial activity to scavenge glutamate toxicity and prevented glial cell senescence and mitochondrial damage, which have recently been reported as critical pathologic features of and therapeutic targets in Parkinson disease (PD) and Alzheimer disease (AD). Along with those anti‐inflammatory/neurotrophic functions, silencing and pharmacological inhibition of SGK1 protected midbrain dopamine neurons from degeneration and cured pathologic synuclein alpha (SNCA) aggregation and PD‐associated behavioral deficits in multiple <i>in vitro</i> and <i>in vivo</i> PD models. Collectively, these findings suggest that SGK1 inhibition could be a useful strategy for treating PD and other neurodegenerative disorders that share the common pathology of glia‐mediated neuroinflammation.</p><p class="para" id="N65541">Pathogenic involvement of SGK1 has been implicated in various neurodegenerative disorders. In this study, we show that inhibition of SGK1 in glia treats Parkinson disease (PD) via suppressing glial inflammation and potentiating glial neurotrophic functions.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766009227970-48f21351-e505-4f8c-b695-4353b09141f2/assets/EMMM-13-e13076-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Urinary proteome profiling for stratifying patients with familial Parkinson’s disease]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766000413440-63876a1b-807f-409b-8ce2-22c9f0aab11e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013257</link>
            <description><![CDATA[<p class="para" id="N65542">The prevalence of Parkinson's disease (PD) is increasing but the development of novel treatment strategies and therapeutics altering the course of the disease would benefit from specific, sensitive, and non‐invasive biomarkers to detect PD early. Here, we describe a scalable and sensitive mass spectrometry (MS)‐based proteomic workflow for urinary proteome profiling. Our workflow enabled the reproducible quantification of more than 2,000 proteins in more than 200 urine samples using minimal volumes from two independent patient cohorts. The urinary proteome was significantly different between PD patients and healthy controls, as well as between <i>LRRK2</i> G2019S carriers and non‐carriers in both cohorts. Interestingly, our data revealed lysosomal dysregulation in individuals with the <i>LRRK2</i> G2019S mutation. When combined with machine learning, the urinary proteome data alone were sufficient to classify mutation status and disease manifestation in mutation carriers remarkably well, identifying VGF, ENPEP, and other PD‐associated proteins as the most discriminating features. Taken together, our results validate urinary proteomics as a valuable strategy for biomarker discovery and patient stratification in PD.</p><p class="para" id="N65541">This study presents a scalable, sensitive and reproducible mass spectrometry‐based proteomics workflow for urinary proteome profiling, and demonstrates it as a promising strategy for urine biomarker discovery for Parkinson’s disease (PD).<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766000413440-63876a1b-807f-409b-8ce2-22c9f0aab11e/assets/EMMM-13-e13257-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Epigenetic gene expression links heart failure to memory impairment]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766000118610-fb381eb5-0228-4c1d-bac6-9320e16c6001/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.201911900</link>
            <description><![CDATA[<p class="para" id="N65542">In current clinical practice, care of diseased patients is often restricted to separated disciplines. However, such an organ‐centered approach is not always suitable. For example, cognitive dysfunction is a severe burden in heart failure patients. Moreover, these patients have an increased risk for age‐associated dementias. The underlying molecular mechanisms are presently unknown, and thus, corresponding therapeutic strategies to improve cognition in heart failure patients are missing. Using mice as model organisms, we show that heart failure leads to specific changes in hippocampal gene expression, a brain region intimately linked to cognition. These changes reflect increased cellular stress pathways which eventually lead to loss of neuronal euchromatin and reduced expression of a hippocampal gene cluster essential for cognition. Consequently, mice suffering from heart failure exhibit impaired memory function. These pathological changes are ameliorated via the administration of a drug that promotes neuronal euchromatin formation. Our study provides first insight to the molecular processes by which heart failure contributes to neuronal dysfunction and point to novel therapeutic avenues to treat cognitive defects in heart failure patients.</p><p class="para" id="N65541">Patients suffering from heart failure have an increased risk to develop age‐associated dementia. This study elucidates the underlying mechanisms and provides evidence that heart‐failure induced cognitive decline is linked to epigenetic changes that affect neuronal gene expression.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1766000118610-fb381eb5-0228-4c1d-bac6-9320e16c6001/assets/EMMM-13-e11900-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The switching mechanism of the bacterial rotary motor combines tight regulation with inherent flexibility]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765999989187-1350ed4a-7a98-45ac-b7a6-ae9fa26392cc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104683</link>
            <description><![CDATA[<p class="para" id="N65542">Regulatory switches are wide spread in many biological systems. Uniquely among them, the switch of the bacterial flagellar motor is not an on/off switch but rather controls the motor’s direction of rotation in response to binding of the signaling protein CheY. Despite its extensive study, the molecular mechanism underlying this switch has remained largely unclear. Here, we resolved the functions of each of the three CheY‐binding sites at the switch in <i>E. coli</i>, as well as their different dependencies on phosphorylation and acetylation of CheY. Based on this, we propose that CheY motor switching activity is potentiated upon binding to the first site. Binding of potentiated CheY to the second site produces unstable switching and at the same time enables CheY binding to the third site, an event that stabilizes the switched state. Thereby, this mechanism exemplifies a unique combination of tight motor regulation with inherent switching flexibility.</p><p class="para" id="N65541">A three‐step mechanism of CheY binding to the <i>E. coli</i> flagellar motor switches bacterial swimming behavior from swimming to tumbling to enable chemotaxis.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765999989187-1350ed4a-7a98-45ac-b7a6-ae9fa26392cc/assets/EMBJ-40-e104683-g001.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[COCO/DAND5 inhibits developmental and pathological ocular angiogenesis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765995342421-78e12425-717f-481c-983f-1a2d38c5ff55/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012005</link>
            <description><![CDATA[<p class="para" id="N65542">Neovascularization contributes to multiple visual disorders including age‐related macular degeneration (AMD) and retinopathy of prematurity. Current therapies for treating ocular angiogenesis are centered on the inhibition of vascular endothelial growth factor (VEGF). While clinically effective, some AMD patients are refractory or develop resistance to anti‐VEGF therapies and concerns of increased risks of developing geographic atrophy following long‐term treatment have been raised. Identification of alternative pathways to inhibit pathological angiogenesis is thus important. We have identified a novel inhibitor of angiogenesis, COCO, a member of the Cerberus‐related DAN protein family. We demonstrate that COCO inhibits sprouting, migration and cellular proliferation of cultured endothelial cells. Intravitreal injections of COCO inhibited retinal vascularization during development and in models of retinopathy of prematurity. COCO equally abrogated angiogenesis in models of choroidal neovascularization. Mechanistically, COCO inhibited TGFβ and BMP pathways and altered energy metabolism and redox balance of endothelial cells. Together, these data show that COCO is an inhibitor of retinal and choroidal angiogenesis, possibly representing a therapeutic option for the treatment of neovascular ocular diseases.</p><p class="para" id="N65541">This study reveals the significant anti‐angiogenic properties of COCO/Dand5 in models of retinal and choroidal neovascularisation. Exogenous COCO inhibited endothelial cell proliferation and migration, limited TGFβ and BMP pathways and altered energy metabolism and cellular redox balance.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765995342421-78e12425-717f-481c-983f-1a2d38c5ff55/assets/EMMM-13-e12005-g016.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Deletions in <i>CWH43</i> cause idiopathic normal pressure hydrocephalus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765995028357-462373da-8c05-4c1d-aa9d-fdeea42519c4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013249</link>
            <description><![CDATA[<p class="para" id="N65542">Idiopathic normal pressure hydrocephalus (iNPH) is a neurological disorder that occurs in about 1% of individuals over age 60 and is characterized by enlarged cerebral ventricles, gait difficulty, incontinence, and cognitive decline. The cause and pathophysiology of iNPH are largely unknown. We performed whole exome sequencing of DNA obtained from 53 unrelated iNPH patients. Two recurrent heterozygous loss of function deletions in <i>CWH43</i> were observed in 15% of iNPH patients and were significantly enriched 6.6‐fold and 2.7‐fold, respectively, when compared to the general population. Cwh43 modifies the lipid anchor of glycosylphosphatidylinositol‐anchored proteins. Mice heterozygous for <i>CWH43</i> deletion appeared grossly normal but displayed hydrocephalus, gait and balance abnormalities, decreased numbers of ependymal cilia, and decreased localization of glycosylphosphatidylinositol‐anchored proteins to the apical surfaces of choroid plexus and ependymal cells. Our findings provide novel mechanistic insights into the origins of iNPH and demonstrate that it represents a distinct disease entity.</p><p class="para" id="N65541">Idiopathic normal pressure hydrocephalus (iNPH) is a neurological disorder of aging characterized by enlarged cerebral ventricles, gait and balance difficulty, incontinence and cognitive impairment. The cause of iNPH is not known.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765995028357-462373da-8c05-4c1d-aa9d-fdeea42519c4/assets/EMMM-13-e13249-g006.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS‐CoV‐2 spike protein]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765994476301-d77837dc-3c55-409f-b3ce-b95259b45c6a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013549</link>
            <description><![CDATA[<p class="para" id="N65542">A correct identification of seropositive individuals for the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection is of paramount relevance to assess the degree of protection of a human population to present and future outbreaks of the COVID‐19 pandemic. We describe here a sensitive and quantitative flow cytometry method using the cytometer‐friendly non‐adherent Jurkat T‐cell line that stably expresses the full‐length native spike “S” protein of SARS‐CoV‐2 and a truncated form of the human EGFR that serves a normalizing role. S protein and huEGFRt coding sequences are separated by a T2A self‐cleaving sequence, allowing to accurately quantify the presence of anti‐S immunoglobulins by calculating a score based on the ratio of fluorescence intensities obtained by double‐staining with the test sera and anti‐EGFR. The method allows to detect immune individuals regardless of the result of other serological tests or even repeated PCR monitoring. As examples of its use, we show that as much as 28% of the personnel working at the CBMSO in Madrid is already immune. Additionally, we show that anti‐S antibodies with protective neutralizing activity are long‐lasting and can be detected in sera 8 months after infection.</p><p class="para" id="N65541">This study shows the development of a new method for the classification of human blood donors according to the presence of anti‐Spike (S) antibodies of SARS‐CoV‐2 that bind to the native S protein expressed on the surface of the human Jurkat human T cell line.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765994476301-d77837dc-3c55-409f-b3ce-b95259b45c6a/assets/EMMM-13-e13549-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Unexpected PD‐L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765994368702-2502bb4b-1a40-464b-b5ac-1dda5aac29c1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012716</link>
            <description><![CDATA[<p class="para" id="N65542">Lack of effective immune infiltration represents a significant barrier to immunotherapy in solid tumors. Thus, solid tumor‐enriched death receptor‐5 (DR5) activating antibodies, which generates tumor debulking by extrinsic apoptotic cytotoxicity, remains a crucial alternate therapeutic strategy. Over past few decades, many DR5 antibodies moved to clinical trials after successfully controlling tumors in immunodeficient tumor xenografts. However, DR5 antibodies failed to significantly improve survival in phase‐II trials, leading in efforts to generate second generation of DR5 agonists to supersize apoptotic cytotoxicity in tumors. Here we have discovered that clinical DR5 antibodies activate an unexpected immunosuppressive PD‐L1 stabilization pathway, which potentially had contributed to their limited success in clinics. The DR5 agonist stimulated caspase‐8 signaling not only activates ROCK1 but also undermines proteasome function, both of which contributes to increased PD‐L1 stability on tumor cell surface. Targeting DR5‐ROCK1‐PD‐L1 axis markedly increases immune effector T‐cell function, promotes tumor regression, and improves overall survival in animal models. These insights have identified a potential clinically viable combinatorial strategy to revive solid cancer immunotherapy using death receptor agonism.</p><p class="para" id="N65541">DR5 agonists moved to clinical trials after successfully controlling tumors in immunodeficient xenograft models. By stabling introducing human DR5 extracellular domain into murine tumor cells, this study identifies PD‐L1 pathway as a contributing factor for potential immune evasion in solid tumors.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765994368702-2502bb4b-1a40-464b-b5ac-1dda5aac29c1/assets/EMMM-13-e12716-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765994004086-811fd445-535e-49d8-afc7-85b59b78cb94/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013180</link>
            <description><![CDATA[<p class="para" id="N65542">Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E‐cadherin. It has clinical features distinct from other estrogen receptor‐positive (ER<sup>+</sup>) breast cancers but the molecular mechanisms underlying its characteristic biology are poorly understood because we lack experimental models to study them. Here, we recapitulate the human disease, including its metastatic pattern, by grafting ILC‐derived breast cancer cell lines, SUM‐44 PE and MDA‐MB‐134‐VI cells, into the mouse milk ducts. Using patient‐derived intraductal xenografts from lobular and non‐lobular ER<sup>+</sup> HER2<sup>−</sup> tumors to compare global gene expression, we identify extracellular matrix modulation as a lobular carcinoma cell‐intrinsic trait. Analysis of TCGA patient datasets shows matrisome signature is enriched in lobular carcinomas with overexpression of elastin, collagens, and the collagen modifying enzyme <i>LOXL1</i>. Treatment with the pan LOX inhibitor BAPN and silencing of <i>LOXL1</i> expression decrease tumor growth, invasion, and metastasis by disrupting ECM structure resulting in decreased ER signaling. We conclude that LOXL1 inhibition is a promising therapeutic strategy for ILC.</p><p class="para" id="N65541">Intraductal xenografts of invasive lobular carcinoma (ILC) cells faithfully model this breast cancer subtype, and reveal tumor cell intrinsic ECM remodeling as a critical feature of disease progression that can be exploited therapeutically by targeting LOXL1.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765994004086-811fd445-535e-49d8-afc7-85b59b78cb94/assets/EMMM-13-e13180-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765993888075-fc8cd119-2b32-44e6-befb-246e71e06eb3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013545</link>
            <description><![CDATA[<p class="para" id="N65542">Precise correction of the <i>CD40LG</i> gene in T cells and hematopoietic stem/progenitor cells (HSPC) holds promise for treating X‐linked hyper‐IgM Syndrome (HIGM1), but its actual therapeutic potential remains elusive. Here, we developed a one‐size‐fits‐all editing strategy for effective T‐cell correction, selection, and depletion and investigated the therapeutic potential of T‐cell and HSPC therapies in the HIGM1 mouse model. Edited patients’ derived CD4 T cells restored physiologically regulated CD40L expression and contact‐dependent B‐cell helper function. Adoptive transfer of wild‐type T cells into conditioned HIGM1 mice rescued antigen‐specific IgG responses and protected mice from a disease‐relevant pathogen. We then obtained ~ 25% <i>CD40LG</i> editing in long‐term repopulating human HSPC. Transplanting such proportion of wild‐type HSPC in HIGM1 mice rescued immune functions similarly to T‐cell therapy. Overall, our findings suggest that autologous edited T cells can provide immediate and substantial benefits to HIGM1 patients and position T‐cell ahead of HSPC gene therapy because of easier translation, lower safety concerns and potentially comparable clinical benefits.</p><p class="para" id="N65541">Here we report a comprehensive set of preclinical studies, performed both <i>in vitro</i> on X‐linked hyper‐IgM syndrome (HIGM1) patient‐derived cells and <i>in vivo</i> in HIGM1 mice, which uncovers crucial guiding principles towards clinical translation of CD40LG targeted gene correction in T cells or hematopoietic stem cells (HSC) for the treatment of HIGM1.<div class="section"><div class="box" id="N65549"><div class="imageVideo"><img src="/dataresources/secured/content-1765993888075-fc8cd119-2b32-44e6-befb-246e71e06eb3/assets/EMMM-13-e13545-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Development of a small molecule that corrects misfolding and increases secretion of Z α<sub>1</sub>‐antitrypsin]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765993560690-5eaabdd6-4fd2-41a4-8a4d-47ad03f0bdbc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013167</link>
            <description><![CDATA[<p class="para" id="N65542">Severe α<sub>1</sub>‐antitrypsin deficiency results from the Z allele (Glu342Lys) that causes the accumulation of homopolymers of mutant α<sub>1</sub>‐antitrypsin within the endoplasmic reticulum of hepatocytes in association with liver disease. We have used a DNA‐encoded chemical library to undertake a high‐throughput screen to identify small molecules that bind to, and stabilise Z α<sub>1</sub>‐antitrypsin. The lead compound blocks Z α<sub>1</sub>‐antitrypsin polymerisation <i>in vitro</i>, reduces intracellular polymerisation and increases the secretion of Z α<sub>1</sub>‐antitrypsin threefold in an iPSC model of disease. Crystallographic and biophysical analyses demonstrate that GSK716 and related molecules bind to a cryptic binding pocket, negate the local effects of the Z mutation and stabilise the bound state against progression along the polymerisation pathway. Oral dosing of transgenic mice at 100 mg/kg three times a day for 20 days increased the secretion of Z α<sub>1</sub>‐antitrypsin into the plasma by sevenfold. There was no observable clearance of hepatic inclusions with respect to controls over the same time period. This study provides proof of principle that “mutation ameliorating” small molecules can block the aberrant polymerisation that underlies Z α<sub>1</sub>‐antitrypsin deficiency.</p><p class="para" id="N65541">A chemistry campaign has developed a small molecule that stabilises the severe Z deficiency mutant of α1‐antitrypsin. The lead compound binds to a cryptic pocket and blocks the conformational change and pathological polymerisation that underlie α1‐antitrypsin deficiency.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765993560690-5eaabdd6-4fd2-41a4-8a4d-47ad03f0bdbc/assets/EMMM-13-e13167-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[
<i>Nanog</i> maintains stemness of <i>Lkb1</i>‐deficient lung adenocarcinoma and prevents gastric differentiation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765993534303-199a7c6d-6e98-49f1-ad2c-46a2ef35f435/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012627</link>
            <description><![CDATA[<p class="para" id="N65542">Growing evidence supports that <i>LKB1</i>‐deficient <i>KRAS</i>‐driven lung tumors represent a unique therapeutic challenge, displaying strong cancer plasticity that promotes lineage conversion and drug resistance. Here we find that murine lung tumors from the <i>Kras<sup>LSL‐G12D/+</sup></i>; <i>Lkb1<sup>flox/flox</sup></i> (KL) model show strong plasticity, which associates with up‐regulation of stem cell pluripotency genes such as <i>Nanog</i>. Deletion of <i>Nanog</i> in KL model initiates a gastric differentiation program and promotes mucinous lung tumor growth. We find that NANOG is not expressed at a meaningful level in human lung adenocarcinoma (ADC), as well as in human lung invasive mucinous adenocarcinoma (IMA). Gastric differentiation involves activation of Notch signaling, and perturbation of Notch pathway by the γ‐secretase inhibitor LY‐411575 remarkably impairs mucinous tumor formation. In contrast to non‐mucinous tumors, mucinous tumors are resistant to phenformin treatment. Such therapeutic resistance could be overcome through combined treatments with LY‐411575 and phenformin. Overall, we uncover a previously unappreciated plasticity of <i>LKB1</i>‐deficient tumors and identify the Nanog‐Notch axis in regulating gastric differentiation, which holds important therapeutic implication for the treatment of mucinous lung cancer.</p><p class="para" id="N65541">This study reveals the plasticity of LKB1‐deficient tumors, and identifies the Nanog‐Notch axis in regulating gastric differentiation. Combinational treatment of γ‐secretase inhibitor LY‐411575 and phenformin effectively blocked invasive mucinous adenocarcinoma IMA formation.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765993534303-199a7c6d-6e98-49f1-ad2c-46a2ef35f435/assets/EMMM-13-e12627-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-13T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[NF45/NF90‐mediated rDNA transcription provides a novel target for immunosuppressant development]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765993426369-08183324-b19c-46fb-a8e8-44d7c03bb103/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012834</link>
            <description><![CDATA[<p class="para" id="N65542">Herein, we demonstrate that NFAT, a key regulator of the immune response, translocates from cytoplasm to nucleolus and interacts with NF45/NF90 complex to collaboratively promote rDNA transcription via triggering the directly binding of NF45/NF90 to the ARRE2‐like sequences in rDNA promoter upon T‐cell activation <i>in vitro</i>. The elevated pre‐rRNA level of T cells is also observed in both mouse heart or skin transplantation models and in kidney transplanted patients. Importantly, T‐cell activation can be significantly suppressed by inhibiting NF45/NF90‐dependent rDNA transcription. Amazingly, CX5461, a rDNA transcription‐specific inhibitor, outperformed FK506, the most commonly used immunosuppressant, both in terms of potency and off‐target activity (i.e., toxicity), as demonstrated by a series of skin and heart allograft models. Collectively, this reveals NF45/NF90‐mediated rDNA transcription as a novel signaling pathway essential for T‐cell activation and as a new target for the development of safe and effective immunosuppressants.</p><p class="para" id="N65541">This study reveals NFAT‐NF45/NF90‐mediated rDNA transcription as a key regulating axis in modulating T cell activation. Targeting ribosome biogenesis could be a novel immunosuppressive therapy for organ transplantation.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765993426369-08183324-b19c-46fb-a8e8-44d7c03bb103/assets/EMMM-13-e12834-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Biofabricating murine and human myo‐substitutes for rapid volumetric muscle loss restoration]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765992972129-50f23ddb-a831-44b0-81cf-f5f59994ef4e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012778</link>
            <description><![CDATA[<p class="para" id="N65542">The importance of skeletal muscle tissue is undoubted being the controller of several vital functions including respiration and all voluntary locomotion activities. However, its regenerative capability is limited and significant tissue loss often leads to a chronic pathologic condition known as volumetric muscle loss. Here, we propose a biofabrication approach to rapidly restore skeletal muscle mass, 3D histoarchitecture, and functionality. By recapitulating muscle anisotropic organization at the microscale level, we demonstrate to efficiently guide cell differentiation and myobundle formation both <i>in vitro</i> and <i>in vivo</i>. Of note, upon implantation, the biofabricated myo‐substitutes support the formation of new blood vessels and neuromuscular junctions—pivotal aspects for cell survival and muscle contractile functionalities—together with an advanced muscle mass and force recovery. Altogether, these data represent a solid base for further testing the myo‐substitutes in large animal size and a promising platform to be eventually translated into clinical scenarios.</p><p class="para" id="N65541">The regenerative capability of skeletal muscle tissue is limited and significant tissue loss often leads to a chronic pathologic condition known as volumetric muscle loss. By exploiting the potentials of our biofabrication approach, one can manufacture advanced cell‐laden myo‐substitutes that ultimately may restore the functionalities of severely damaged skeletal muscles <i>in vivo</i>.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765992972129-50f23ddb-a831-44b0-81cf-f5f59994ef4e/assets/EMMM-13-e12778-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Therapeutic development of group B <i>Streptococcus</i> meningitis by targeting a host cell signaling network involving EGFR]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765992554046-4b1e83af-c4df-467e-bb58-4eb487c491f8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012651</link>
            <description><![CDATA[<p class="para" id="N65542">Group B <i>Streptococcus</i> (GBS) remains the most common Gram‐positive bacterium causing neonatal meningitis and GBS meningitis continues to be an important cause of mortality and morbidity. In this study, we showed that GBS penetration into the brain occurred initially in the meningeal and cortex capillaries, and exploits a defined host cell signaling network comprised of S1P<sub>2</sub>, EGFR, and CysLT1. GBS exploitation of such network in penetration of the blood–brain barrier was demonstrated by targeting S1P<sub>2</sub>, EGFR, and CysLT1 using pharmacological inhibition, gene knockout and knockdown cells, and gene knockout animals, as well as interrogation of the network (up‐ and downstream of each other). More importantly, counteracting such targets as a therapeutic adjunct to antibiotic therapy was beneficial in improving the outcome of animals with GBS meningitis. These findings indicate that investigating GBS penetration of the blood–brain barrier provides a novel approach for therapeutic development of GBS meningitis.</p><p class="para" id="N65541">Group B <i>Streptococci</i> (GBS) exploit specific host factors S1P2, EGFR and CysLT1 to penetrate the blood‐brain barrier, which is the essential step in the development of GBS meningitis. These host factors function as a distinct network, with S1P2 and CysLT1 acting as upstream and downstream molecules of EGFR.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765992554046-4b1e83af-c4df-467e-bb58-4eb487c491f8/assets/EMMM-13-e12651-g010.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A sensory cell diversifies its output by varying Ca<sup>2+</sup> influx‐release coupling among active zones]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765969567703-ba699ea9-5016-4161-b13f-0a68cbdcfe53/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020106010</link>
            <description><![CDATA[<p class="para" id="N65542">The cochlea encodes sound pressures varying over six orders of magnitude by collective operation of functionally diverse spiral ganglion neurons (SGNs). The mechanisms enabling this functional diversity remain elusive. Here, we asked whether the sound intensity information, contained in the receptor potential of the presynaptic inner hair cell (IHC), is fractionated via heterogeneous synapses. We studied the transfer function of individual IHC synapses by combining patch‐clamp recordings with dual‐color Rhod‐FF and iGluSnFR imaging of presynaptic Ca<sup>2+</sup> signals and glutamate release. Synapses differed in the voltage dependence of release: Those residing at the IHC' pillar side activated at more hyperpolarized potentials and typically showed tight control of release by few Ca<sup>2+</sup> channels. We conclude that heterogeneity of voltage dependence and release site coupling of Ca<sup>2+</sup> channels among the synapses varies synaptic transfer within individual IHCs and, thereby, likely contributes to the functional diversity of SGNs. The mechanism reported here might serve sensory cells and neurons more generally to diversify signaling even in close‐by synapses.</p><p class="para" id="N65541">Analysis of individual synapses reveal that the ability of auditory inner hair cells to translate a wide range of sound intensities is linked to presynaptic heterogeneity in Ca<sup>2+</sup> channel‐mediated glutamate release.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765969567703-ba699ea9-5016-4161-b13f-0a68cbdcfe53/assets/EMBJ-40-e106010-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The RNA polymerase II subunit RPB‐9 recruits the integrator complex to terminate <i>Caenorhabditis elegans</i> piRNA transcription]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765969546923-63361450-48b0-432f-bc3c-fa462cb2d6fd/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105565</link>
            <description><![CDATA[<p class="para" id="N65542">PIWI‐interacting RNAs (piRNAs) are genome‐encoded small RNAs that regulate germ cell development and maintain germline integrity in many animals. Mature piRNAs engage Piwi Argonaute proteins to silence complementary transcripts, including transposable elements and endogenous genes. piRNA biogenesis mechanisms are diverse and remain poorly understood. Here, we identify the RNA polymerase II (RNA Pol II) core subunit RPB‐9 as required for piRNA‐mediated silencing in the nematode <i>Caenorhabditis elegans</i>. We show that <i>rpb‐9</i> initiates heritable piRNA‐mediated gene silencing at two DNA transposon families and at a subset of somatic genes in the germline. We provide genetic and biochemical evidence that RPB‐9 is required for piRNA biogenesis by recruiting the Integrator complex at piRNA genes, hence promoting transcriptional termination. We conclude that, as a part of its rapid evolution, the piRNA pathway has co‐opted an ancient machinery for high‐fidelity transcription.</p><p class="para" id="N65541">piRNA biogenesis requires RBP‐9 mediated transcriptional termination at complex piRNA genes.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765969546923-63361450-48b0-432f-bc3c-fa462cb2d6fd/assets/EMBJ-40-e105565-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765968994771-a90d6663-cbf8-4285-bcad-3f7d3ce3df30/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020106228</link>
            <description><![CDATA[<p class="para" id="N65542">Nucleoprotein (N) is an immunodominant antigen in many enveloped virus infections. While the diagnostic value of anti‐N antibodies is clear, their role in immunity is not. This is because while they are non‐neutralising, they somehow clear infection by coronavirus, influenza and LCMV <i>in vivo</i>. Here, we show that anti‐N immune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21. Exploiting LCMV as a model system, we demonstrate that TRIM21 uses anti‐N antibodies to target N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide. These CTLs rapidly eliminate N‐peptide‐displaying cells and drive efficient viral clearance. These results reveal a new mechanism of immune synergy between antibodies and T cells and highlights N as an important vaccine target.</p><p class="para" id="N65541">Cytosolic antibody receptor and ubiquitin ligase TRIM21 promotes antigen presentation and T cell activation by targeting immune complexes for efficient proteasomal degradation.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765968994771-a90d6663-cbf8-4285-bcad-3f7d3ce3df30/assets/EMBJ-40-e106228-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Integrator is recruited to promoter‐proximally paused RNA Pol II to generate <i>Caenorhabditis elegans</i> piRNA precursors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765968921785-980ec940-cb85-4072-8f4b-7f97593012e7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105564</link>
            <description><![CDATA[<p class="para" id="N65542">Piwi‐interacting RNAs (piRNAs) play key roles in germline development and genome defence in metazoans. In <i>C. elegans</i>, piRNAs are transcribed from &gt; 15,000 discrete genomic loci by RNA polymerase II (Pol II), resulting in 28 nt short‐capped piRNA precursors. Here, we investigate transcription termination at piRNA loci. We show that the Integrator complex, which terminates snRNA transcription, is recruited to piRNA loci. Moreover, we demonstrate that the catalytic activity of Integrator cleaves nascent capped piRNA precursors associated with promoter‐proximal Pol II, resulting in termination of transcription. Loss of Integrator activity, however, does not result in transcriptional readthrough at the majority of piRNA loci. Taken together, our results draw new parallels between snRNA and piRNA biogenesis in nematodes and provide evidence of a role for the Integrator complex as a terminator of promoter‐proximal RNA polymerase II during piRNA biogenesis.</p><p class="para" id="N65541">Transcription termination and release of short capped piRNA precursors extends the small RNA biogenesis roles of the Integrator complex beyond snRNA.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765968921785-980ec940-cb85-4072-8f4b-7f97593012e7/assets/EMBJ-40-e105564-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a <i>Shank2</i> mouse model for autism]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765968874523-afee73ca-b449-4e13-9336-a9fad9dcbedf/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2019104267</link>
            <description><![CDATA[<p class="para" id="N65542">Impairments in social relationships and awareness are features observed in autism spectrum disorders (ASDs). However, the underlying mechanisms remain poorly understood. Shank2 is a high‐confidence ASD candidate gene and localizes primarily to postsynaptic densities (PSDs) of excitatory synapses in the central nervous system (CNS). We show here that loss of Shank2 in mice leads to a lack of social attachment and bonding behavior towards pubs independent of hormonal, cognitive, or sensitive deficits. <i>Shank2</i>
<sup>−/−</sup> mice display functional changes in nuclei of the social attachment circuit that were most prominent in the medial preoptic area (MPOA) of the hypothalamus. Selective enhancement of MPOA activity by DREADD technology re‐established social bonding behavior in <i>Shank2</i>
<sup>−/−</sup> mice, providing evidence that the identified circuit might be crucial for explaining how social deficits in ASD can arise.</p><p class="para" id="N65541">Loss of the autism spectrum disorders linked gene <i>Shank2</i> in mice leads to loss of social bonding due to functional changes in the social attachment circuit including the MPOA.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765968874523-afee73ca-b449-4e13-9336-a9fad9dcbedf/assets/EMBJ-40-e104267-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The eukaryotic replisome tolerates leading‐strand base damage by replicase switching]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765968737688-d574ec3d-da68-4774-9049-b91a884f9783/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020107037</link>
            <description><![CDATA[<p class="para" id="N65542">The high‐fidelity replicative DNA polymerases, Pol ε and Pol δ, are generally thought to be poorly equipped to replicate damaged DNA. Direct and complete replication of a damaged template therefore typically requires the activity of low‐fidelity translesion synthesis (TLS) polymerases. Here we show that a yeast replisome, reconstituted with purified proteins, is inherently tolerant of the common oxidative lesion thymine glycol (Tg). Surprisingly, leading‐strand Tg was bypassed efficiently in the presence and absence of the TLS machinery. Our data reveal that following helicase–polymerase uncoupling a switch from Pol ε, the canonical leading‐strand replicase, to the lagging‐strand replicase Pol δ, facilitates rapid, efficient and error‐free lesion bypass at physiological nucleotide levels. This replicase switch mechanism also promotes bypass of the unrelated oxidative lesion, 8‐oxoguanine. We propose that replicase switching may promote continued leading‐strand synthesis whenever the replisome encounters leading‐strand damage that is bypassed more efficiently by Pol δ than by Pol ε.</p><p class="para" id="N65541">The common oxidative DNA base lesion thymine glycol can surprisingly be bypassed by reconstituted yeast replisomes in the absence of dedicated translesion synthesis polymerases.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765968737688-d574ec3d-da68-4774-9049-b91a884f9783/assets/EMBJ-40-e107037-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Reverse fountain flow of phosphatidylinositol‐3,4‐bisphosphate polarizes migrating cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765881606543-ce4f31ed-54fb-472c-ac16-fbda5a8f2186/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105094</link>
            <description><![CDATA[<p class="para" id="N65542">The ability of cells to polarize and move toward external stimuli plays a crucial role in development, as well as in normal and pathological physiology. Migrating cells maintain dynamic complementary distributions of Ras activity and of the phospholipid phosphatidylinositol‐3,4‐bisphosphate (PI(3,4)P2). Here, we show that lagging‐edge component PI(3,4)P2 also localizes to retracting leading‐edge protrusions and nascent macropinosomes, even in the absence of phosphatidylinositol 3,4,5‐trisphosphate (PIP3). Once internalized, macropinosomes break up into smaller PI(3,4)P2‐enriched vesicles, which fuse with the plasma membrane at the rear of the cell. Subsequently, the phosphoinositide diffuses toward the front of the cell, where it is degraded. Computational modeling confirms that this cycle gives rise to stable back‐to‐front gradient. These results uncover a surprising “reverse‐fountain flow” of PI(3,4)P2 that regulates polarity.</p><p class="para" id="N65541">Macropinosome‐dependent delivery of the phospholipid PI(3,4)P2 to the trailing edge of the cell establishes its polarized distribution required for correct migratory behavior.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765881606543-ce4f31ed-54fb-472c-ac16-fbda5a8f2186/assets/EMBJ-40-e105094-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-02-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Crystal structure of bacterial cytotoxic necrotizing factor CNF<sub>Y</sub> reveals molecular building blocks for intoxication]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879897178-dbad300e-00bb-45c1-a9aa-a677999385f6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105202</link>
            <description><![CDATA[<p class="para" id="N65542">Cytotoxic necrotizing factors (CNFs) are bacterial single‐chain exotoxins that modulate cytokinetic/oncogenic and inflammatory processes through activation of host cell Rho GTPases. To achieve this, they are secreted, bind surface receptors to induce endocytosis and translocate a catalytic unit into the cytosol to intoxicate host cells. A three‐dimensional structure that provides insight into the underlying mechanisms is still lacking. Here, we determined the crystal structure of full‐length <i>Yersinia pseudotuberculosis</i> CNF<sub>Y</sub>. CNF<sub>Y</sub> consists of five domains (D1–D5), and by integrating structural and functional data, we demonstrate that D1–3 act as export and translocation module for the catalytic unit (D4–5) and for a fused β‐lactamase reporter protein. We further found that D4, which possesses structural similarity to ADP‐ribosyl transferases, but had no equivalent catalytic activity, changed its position to interact extensively with D5 in the crystal structure of the free D4–5 fragment. This liberates D5 from a semi‐blocked conformation in full‐length CNF<sub>Y</sub>, leading to higher deamidation activity. Finally, we identify CNF translocation modules in several uncharacterized fusion proteins, which suggests their usability as a broad‐specificity protein delivery tool.</p><p class="para" id="N65541">Structure‐function analyses of the full‐length <i>Yersinia pseudotuberculosis</i> toxin CNFY offer insights into individual domain contributions to stepwise receptor binding, endocytosis, and translocation into the host cell cytosol.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765879897178-dbad300e-00bb-45c1-a9aa-a677999385f6/assets/EMBJ-40-e105202-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879821047-59dec7b6-974f-4941-b7a6-229a0c27520b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105375</link>
            <description><![CDATA[<p class="para" id="N65542">Thalidomide causes teratogenic effects by inducing protein degradation via cereblon (CRBN)‐containing ubiquitin ligase and modification of its substrate specificity. Human P450 cytochromes convert thalidomide into two monohydroxylated metabolites that are considered to contribute to thalidomide effects, through mechanisms that remain unclear. Here, we report that promyelocytic leukaemia zinc finger (PLZF)/ZBTB16 is a CRBN target protein whose degradation is involved in thalidomide‐ and 5‐hydroxythalidomide‐induced teratogenicity. Using a human transcription factor protein array produced in a wheat cell‐free protein synthesis system, PLZF was identified as a thalidomide‐dependent CRBN substrate. PLZF is degraded by the ubiquitin ligase CRL4<sup>CRBN</sup> in complex with thalidomide, its derivatives or 5‐hydroxythalidomide in a manner dependent on the conserved first and third zinc finger domains of PLZF. Surprisingly, thalidomide and 5‐hydroxythalidomide confer distinctly different substrate specificities to mouse and chicken CRBN, and both compounds cause teratogenic phenotypes in chicken embryos. Consistently, knockdown of <i>Plzf</i> induces short bone formation in chicken limbs. Most importantly, degradation of PLZF protein, but not of the known thalidomide‐dependent CRBN substrate SALL4, was induced by thalidomide or 5‐hydroxythalidomide treatment in chicken embryos. Furthermore, PLZF overexpression partially rescued the thalidomide‐induced phenotypes. Our findings implicate PLZF as an important thalidomide‐induced CRBN neosubstrate involved in thalidomide teratogenicity.</p><p class="para" id="N65541">The vertebrate transcription factor PLZF/ZBTB16 emerges as potential key mediator of limb defects caused by CRBN ubiquitin ligase modulators, providing insight into the teratogenic contributions of thalidomide metabolites.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765879821047-59dec7b6-974f-4941-b7a6-229a0c27520b/assets/EMBJ-40-e105375-g016.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Steroid‐dependent switch of OvoL/Shavenbaby controls self‐renewal versus differentiation of intestinal stem cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879618700-ec97896f-f9d0-4e54-9924-afd68359a8e1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2019104347</link>
            <description><![CDATA[<p class="para" id="N65542">Adult stem cells must continuously fine‐tune their behavior to regenerate damaged organs and avoid tumors. While several signaling pathways are well known to regulate somatic stem cells, the underlying mechanisms remain largely unexplored. Here, we demonstrate a cell‐intrinsic role for the OvoL family transcription factor, Shavenbaby (Svb), in balancing self‐renewal and differentiation of <i>Drosophila</i> intestinal stem cells. We find that <i>svb</i> is a downstream target of Wnt and EGFR pathways, mediating their activity for stem cell survival and proliferation. This requires post‐translational processing of Svb into a transcriptional activator, whose upregulation induces tumor‐like stem cell hyperproliferation. In contrast, the unprocessed form of Svb acts as a repressor that imposes differentiation into enterocytes, and suppresses tumors induced by altered signaling. We show that the switch between Svb repressor and activator is triggered in response to systemic steroid hormone, which is produced by ovaries. Therefore, the Svb axis allows intrinsic integration of local signaling cues and inter‐organ communication to adjust stem cell proliferation <i>versus</i> differentiation, suggesting a broad role of OvoL/Svb in adult and cancer stem cells.</p><p class="para" id="N65541">Post‐translational processing of the transcription factor Shavenbaby defines its dichotomous function in fly midgut homeostasis.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765879618700-ec97896f-f9d0-4e54-9924-afd68359a8e1/assets/EMBJ-40-e104347-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Centriolar distal appendages activate the centrosome‐PIDDosome‐p53 signalling axis via ANKRD26]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878608221-c6ce5a73-aff4-4a7a-8e2a-eb765b686abc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104844</link>
            <description><![CDATA[<p class="para" id="N65542">Centrosome amplification results into genetic instability and predisposes cells to neoplastic transformation. Supernumerary centrosomes trigger p53 stabilization dependent on the PIDDosome (a multiprotein complex composed by PIDD1, RAIDD and Caspase‐2), whose activation results in cleavage of p53’s key inhibitor, MDM2. Here, we demonstrate that PIDD1 is recruited to mature centrosomes by the centriolar distal appendage protein ANKRD26. PIDDosome‐dependent Caspase‐2 activation requires not only PIDD1 centrosomal localization, but also its autoproteolysis. Following cytokinesis failure, supernumerary centrosomes form clusters, which appear to be necessary for PIDDosome activation. In addition, in the context of DNA damage, activation of the complex results from a p53‐dependent elevation of PIDD1 levels independently of centrosome amplification. We propose that PIDDosome activation can in both cases be promoted by an ANKRD26‐dependent local increase in PIDD1 concentration close to the centrosome. Collectively, these findings provide a paradigm for how centrosomes can contribute to cell fate determination by igniting a signalling cascade.</p><p class="para" id="N65541">ANKRD26‐dependent PIDD1 recruitment is involved in p53 activation both upon genotoxic stress and in the presence of supernumerary centrosomes.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765878608221-c6ce5a73-aff4-4a7a-8e2a-eb765b686abc/assets/EMBJ-40-e104844-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Ythdf is a N6‐methyladenosine reader that modulates Fmr1 target mRNA selection and restricts axonal growth in <i>Drosophila</i>
]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878048321-599048d9-7828-4af7-a656-ff2fdf23040d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104975</link>
            <description><![CDATA[<p class="para" id="N65542">N6‐methyladenosine (m<sup>6</sup>A) regulates a variety of physiological processes through modulation of RNA metabolism. This modification is particularly enriched in the nervous system of several species, and its dysregulation has been associated with neurodevelopmental defects and neural dysfunctions. In <i>Drosophila</i>, loss of m<sup>6</sup>A alters fly behavior, albeit the underlying molecular mechanism and the role of m<sup>6</sup>A during nervous system development have remained elusive. Here we find that impairment of the m<sup>6</sup>A pathway leads to axonal overgrowth and misguidance at larval neuromuscular junctions as well as in the adult mushroom bodies. We identify Ythdf as the main m<sup>6</sup>A reader in the nervous system, being required to limit axonal growth. Mechanistically, we show that the m<sup>6</sup>A reader Ythdf directly interacts with Fmr1, the fly homolog of Fragile X mental retardation RNA binding protein (FMRP), to inhibit the translation of key transcripts involved in axonal growth regulation. Altogether, this study demonstrates that the m<sup>6</sup>A pathway controls development of the nervous system and modulates Fmr1 target transcript selection.</p><p class="para" id="N65541">Proper neuromuscular junction formation in flies depends on a key mRNA modification guiding translational repression by the Fragile X mental retardation (FMRP) RNA‐binding protein.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765878048321-599048d9-7828-4af7-a656-ff2fdf23040d/assets/EMBJ-40-e104975-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Neonatal AAV gene therapy rescues hearing in a mouse model of <i>SYNE4</i> deafness]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862599338-40205993-a83f-4a83-ae21-29e8589dae60/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013259</link>
            <description><![CDATA[<p class="para" id="N65542">Genetic variants account for approximately half the cases of congenital and early‐onset deafness. Methods and technologies for viral delivery of genes into the inner ear have evolved over the past decade to render gene therapy a viable and attractive approach for treatment. Variants in <i>SYNE4</i>, encoding the protein nesprin‐4, a member of the linker of nucleoskeleton and cytoskeleton (LINC), lead to DFNB76 human deafness. <i>Syne4</i>
<sup>−/−</sup> mice have severe‐to‐profound progressive hearing loss and exhibit mislocalization of hair cell nuclei and hair cell degeneration. We used AAV9‐PHP.B, a recently developed synthetic adeno‐associated virus, to deliver the coding sequence of <i>Syne4</i> into the inner ears of neonatal <i>Syne4</i>
<sup>−/−</sup> mice. Here we report rescue of hair cell morphology and survival, nearly complete recovery of auditory function, and restoration of auditory‐associated behaviors, without observed adverse effects. Uncertainties remain regarding the durability of the treatment and the time window for intervention in humans, but our results suggest that gene therapy has the potential to prevent hearing loss in humans with <i>SYNE4</i> mutations.</p><p class="para" id="N65541">Syne4 deficiency leads to hearing loss in humans. In this work, auditory function was rescued in <i>Syne4</i> knockout mice by a synthetic AAV that enables safe and efficient transduction of hair cells in the cochlea.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765862599338-40205993-a83f-4a83-ae21-29e8589dae60/assets/EMMM-13-e13259-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862386714-d7e76bc7-272a-41f6-83fe-b96dee88474d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.201911902</link>
            <description><![CDATA[<p class="para" id="N65542">The prostate‐specific membrane antigen (PSMA) has been demonstrated in numerous studies to be expressed specifically on prostate carcinoma cells and on the neovasculature of several other cancer entities. However, the simultaneous expression of PSMA on both, tumor cells as well as tumor vessels remains unclear, even if such “dual” expression would constitute an important asset to facilitate sufficient influx of effector cells to a given tumor site. We report here on the generation of a PSMA antibody, termed 10B3, which exerts superior dual reactivity on sections of prostate carcinoma and squamous cell carcinoma of the lung. 10B3 was used for the construction of T‐cell recruiting bispecific PSMAxCD3 antibodies in Fab‐ and IgG‐based formats, designated Fabsc and IgGsc, respectively. <i>In vitro</i>, both molecules exhibited comparable activity. In contrast, only the larger IgGsc molecule induced complete and durable elimination of established tumors in humanized mice due to favorable pharmacokinetic properties. Upon treatment of three patients with metastasized prostate carcinoma with the IgGsc reagent, marked activation of T cells and rapid reduction of elevated PSA levels were observed.</p><p class="para" id="N65541">Insufficient penetration of immune cells and therapeutic antibodies into the tumor core is a major limitation in the immunotherapy field. This study reports the development of a novel bispecific antibody, named CC‐1, for improved dual targeting of tumor‐ and vascular cells in PSMA positive tumors.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765862386714-d7e76bc7-272a-41f6-83fe-b96dee88474d/assets/EMMM-13-e11902-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeted attenuation of elevated histone marks at <i>SNCA</i> alleviates α‐synuclein in Parkinson's disease]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862366105-70f42797-f6a7-42e5-94c5-d64606263069/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012188</link>
            <description><![CDATA[<p class="para" id="N65542">Epigenetic deregulation of α‐synuclein plays a key role in Parkinson’s disease (PD). Analysis of the <i>SNCA</i> promoter using the ENCODE database revealed the presence of important histone post‐translational modifications (PTMs) including transcription‐promoting marks, H3K4me3 and H3K27ac, and repressive mark, H3K27me3. We investigated these histone marks in post‐mortem brains of controls and PD patients and observed that only H3K4me3 was significantly elevated at the <i>SNCA</i> promoter of the substantia nigra (SN) of PD patients both in punch biopsy and in NeuN‐positive neuronal nuclei samples. To understand the importance of H3K4me3 in regulation of α‐synuclein, we developed CRISPR/dCas9‐based locus‐specific H3K4me3 demethylating system where the catalytic domain of JARID1A was recruited to the <i>SNCA</i> promoter. This CRISPR/dCas9 SunTag‐JARID1A significantly reduced H3K4me3 at <i>SNCA</i> promoter and concomitantly decreased α‐synuclein both in the neuronal cell line SH‐SY5Y and idiopathic PD‐iPSC derived dopaminergic neurons. In sum, this study indicates that α‐synuclein expression in PD is controlled by <i>SNCA</i>’s histone PTMs and modulation of the histone landscape of <i>SNCA</i> can reduce α‐synuclein expression.</p><p class="para" id="N65541">Histone posttranslational modifications play a major role in the regulation of α‐synuclein expression in Parkinson’s disease (PD). Locus‐specific editing of H3K4me3 at the <i>SNCA</i> promoter reverts the deregulated expression of α‐synuclein in neurons in the context of PD.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765862366105-70f42797-f6a7-42e5-94c5-d64606263069/assets/EMMM-13-e12188-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862222326-95ddc7db-12d7-4e06-9636-6280da791dda/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012632</link>
            <description><![CDATA[<p class="para" id="N65542">Glycine transporters (GlyT1 and GlyT2) that regulate levels of brain glycine, an inhibitory neurotransmitter with co‐agonist activity for NMDA receptors (NMDARs), have been considered to be important targets for the treatment of brain disorders with suppressed NMDAR function such as schizophrenia. However, it remains unclear whether other amino acid transporters expressed in the brain can also regulate brain glycine levels and NMDAR function. Here, we report that SLC6A20A, an amino acid transporter known to transport proline based on <i>in vitro</i> data but is understudied in the brain, regulates proline and glycine levels and NMDAR function in the mouse brain. SLC6A20A transcript and protein levels were abnormally increased in mice carrying a mutant PTEN protein lacking the C terminus through enhanced β‐catenin binding to the <i>Slc6a20a</i> gene. These mice displayed reduced extracellular levels of brain proline and glycine and decreased NMDAR currents. Elevating glycine levels back to normal ranges by antisense oligonucleotide‐induced SLC6A20 knockdown, or the competitive GlyT1 antagonist sarcosine, normalized NMDAR currents and repetitive climbing behavior observed in these mice. Conversely, mice lacking SLC6A20A displayed increased extracellular glycine levels and NMDAR currents. Lastly, both mouse and human SLC6A20 proteins mediated proline and glycine transports, and SLC6A20 proteins could be detected in human neurons. These results suggest that SLC6A20 regulates proline and glycine homeostasis in the brain and that SLC6A20 inhibition has therapeutic potential for brain disorders involving NMDAR hypofunction.</p><p class="para" id="N65541">This study reveals that SLC6A20A, an amino acid transporter previously known to transport proline, also transports glycine, a co‐agonist of NMDA receptors. SLC6A20A inhibition holds therapeutic potential for brain disorders with suppressed NMDAR function such as schizophrenia.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765862222326-95ddc7db-12d7-4e06-9636-6280da791dda/assets/EMMM-13-e12632-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862176870-680e84b8-c8c4-403e-807c-f24720bc62a6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.201910852</link>
            <description><![CDATA[<p class="para" id="N65542">The tumor suppressor gene <i>TP53</i> is the most frequently mutated gene in cancer. The compound APR‐246 (PRIMA‐1Met/Eprenetapopt) is converted to methylene quinuclidinone (MQ) that targets mutant p53 protein and perturbs cellular antioxidant balance. APR‐246 is currently tested in a phase III clinical trial in myelodysplastic syndrome (MDS). By <i>in vitro</i>, <i>ex vivo,</i> and <i>in vivo</i> models, we show that combined treatment with APR‐246 and inhibitors of efflux pump MRP1/ABCC1 results in synergistic tumor cell death, which is more pronounced in <i>TP53</i> mutant cells. This is associated with altered cellular thiol status and increased intracellular glutathione‐conjugated MQ (GS‐MQ). Due to the reversibility of MQ conjugation, GS‐MQ forms an intracellular drug reservoir that increases availability of MQ for targeting mutant p53. Our study shows that redox homeostasis is a critical determinant of the response to mutant p53‐targeted cancer therapy.</p><p class="para" id="N65541">Tumor suppressor <i>TP53</i> is mutated in a large fraction of tumors. APR‐246/Eprenetapopt is the most clinically advanced mutant p53‐targeting drug candidate (Phase III). Besides restoring wild type p53 activity, the active product MQ also disrupts the redox balance, resulting in cancer cell death.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765862176870-680e84b8-c8c4-403e-807c-f24720bc62a6/assets/EMMM-13-e10852-g016.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862168347-b4a8c88d-3bc7-4a54-b6dc-7a1016d53eae/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013492</link>
            <description><![CDATA[<p class="para" id="N65542">Vegan diets are gaining popularity, also in families with young children. However, the effects of strict plant‐based diets on metabolism and micronutrient status of children are unknown. We recruited 40 Finnish children with a median age 3.5 years—vegans, vegetarians, or omnivores from same daycare centers—for a cross‐sectional study. They enjoyed nutritionist‐planned vegan or omnivore meals in daycare, and the full diets were analyzed with questionnaires and food records. Detailed analysis of serum metabolomics and biomarkers indicated vitamin A insufficiency and border‐line sufficient vitamin D in all vegan participants. Their serum total, HDL and LDL cholesterol, essential amino acid, and docosahexaenoic n‐3 fatty acid (DHA) levels were markedly low and primary bile acid biosynthesis, and phospholipid balance was distinct from omnivores. Possible combination of low vitamin A and DHA status raise concern for their visual health. Our evidence indicates that (i) vitamin A and D status of vegan children requires special attention; (ii) dietary recommendations for children cannot be extrapolated from adult vegan studies; and (iii) longitudinal studies on infant‐onset vegan diets are warranted.</p><p class="para" id="N65541">Nutritional and metabolic effects of strict vegan diets in young children are poorly understood. This first cross‐sectional study of preschool children reports that vegan diet remodels metabolome and lipidome and raises concern of their vitamin A and D statuses and essential amino acids.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765862168347-b4a8c88d-3bc7-4a54-b6dc-7a1016d53eae/assets/EMMM-13-e13492-g007.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Attenuated CSF‐1R signalling drives cerebrovascular pathology]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862148098-d9961c88-80b5-4b24-8b5e-e3626e7f8550/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012889</link>
            <description><![CDATA[<p class="para" id="N65542">Cerebrovascular pathologies occur in up to 80% of cases of Alzheimer's disease; however, the underlying mechanisms that lead to perivascular pathology and accompanying blood–brain barrier (BBB) disruption are still not fully understood. We have identified previously unreported mutations in colony stimulating factor‐1 receptor (<i>CSF‐1R</i>) in an ultra‐rare autosomal dominant condition termed adult‐onset leucoencephalopathy with axonal spheroids and pigmented glia (ALSP). Cerebrovascular pathologies such as cerebral amyloid angiopathy (CAA) and perivascular p‐Tau were some of the primary neuropathological features of this condition. We have identified two families with different dominant acting alleles with variants located in the kinase region of the <i>CSF‐1R</i> gene, which confer a lack of kinase activity and signalling. The protein product of this gene acts as the receptor for 2 cognate ligands, namely colony stimulating factor‐1 (CSF‐1) and interleukin‐34 (IL‐34). Here, we show that depletion in CSF‐1R signalling induces BBB disruption and decreases the phagocytic capacity of peripheral macrophages but not microglia. CSF‐1R signalling appears to be critical for macrophage and microglial activation, and macrophage localisation to amyloid appears reduced following the induction of <i>Csf‐1r</i> heterozygosity in macrophages. Finally, we show that endothelial/microglial crosstalk and concomitant attenuation of CSF‐1R signalling causes re‐modelling of BBB‐associated tight junctions and suggest that regulating BBB integrity and systemic macrophage recruitment to the brain may be therapeutically relevant in ALSP and other Alzheimer’s‐like dementias.</p><p class="para" id="N65541">Two familial cohorts of ALSP, with novel pathological CSF1R variants were examined and an associating cerebrovascular amyloid‐β pathology identified. Deficits in peripheral macrophage function and blood‐brain barrier maintenance identified and suggested to contribute to ALSP.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765862148098-d9961c88-80b5-4b24-8b5e-e3626e7f8550/assets/EMMM-13-e12889-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Beclin‐1‐mediated activation of autophagy improves proximal and distal urea cycle disorders]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765862029166-680c867e-d174-4356-be3d-a5e18a3c7cbd/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013158</link>
            <description><![CDATA[<p class="para" id="N65542">Urea cycle disorders (UCD) are inherited defects in clearance of waste nitrogen with high morbidity and mortality. Novel and more effective therapies for UCD are needed. Studies in mice with constitutive activation of autophagy unravelled Beclin‐1 as <i>druggable</i> candidate for therapy of hyperammonemia. Next, we investigated efficacy of cell‐penetrating autophagy‐inducing Tat‐Beclin‐1 (TB‐1) peptide for therapy of the two most common UCD, namely ornithine transcarbamylase (OTC) and argininosuccinate lyase (ASL) deficiencies. TB‐1 reduced urinary orotic acid and improved survival under protein‐rich diet in <i>spf‐ash</i> mice, a model of OTC deficiency (proximal UCD). In <i>Asl<sup>Neo/Neo</sup></i> mice, a model of ASL deficiency (distal UCD), TB‐1 increased ureagenesis, reduced argininosuccinate, and improved survival. Moreover, it alleviated hepatocellular injury and decreased both cytoplasmic and nuclear glycogen accumulation in <i>Asl<sup>Neo/Neo</sup></i> mice. In conclusion, Beclin‐1‐dependent activation of autophagy improved biochemical and clinical phenotypes of proximal and distal defects of the urea cycle.</p><p class="para" id="N65541">Using mice with constitutive activation of autophagy and treating mice deficient for ornithine transcarbamylase (OTC) and argininosuccinate lyase (ASL) with the autophagy inducing Tat‐Beclin‐1 (TB‐1), this study shows that Beclin‐1‐dependent activation of autophagy improves the phenotypes of proximal and distal defects of the urea cycle.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765862029166-680c867e-d174-4356-be3d-a5e18a3c7cbd/assets/EMMM-13-e13158-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765861843367-d66a6e4c-aaa9-4051-8886-73d6bba7d753/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012640</link>
            <description><![CDATA[<p class="para" id="N65542">Rhabdoid tumor (RT) is a pediatric cancer characterized by the inactivation of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. Although this deletion is the known oncogenic driver, there are limited effective therapeutic options for these patients. Here we use unbiased screening of cell line panels to identify a heightened sensitivity of rhabdoid tumor to mithramycin and the second‐generation analogue EC8042. The sensitivity of MMA and EC8042 was superior to traditional DNA damaging agents and linked to the causative mutation of the tumor, SMARCB1 deletion. Mithramycin blocks SMARCB1‐deficient SWI/SNF activity and displaces the complex from chromatin to cause an increase in H3K27me3. This triggers chromatin remodeling and enrichment of H3K27ac at chromHMM‐defined promoters to restore cellular differentiation. These effects occurred at concentrations not associated with DNA damage and were not due to global chromatin remodeling or widespread gene expression changes. Importantly, a single 3‐day infusion of EC8042 caused dramatic regressions of RT xenografts, recapitulated the increase in H3K27me3, and cellular differentiation described <i>in vitro</i> to completely cure three out of eight mice.</p><p class="para" id="N65541">EC8042 is identified as an inhibitor of oncogenic SWI/SNF and a promising therapeutic candidate for rhabdoid tumor. The mechanism of target inhibition is elucidated and used to optimize compound administration, characterize an associated biomarker, and cure mice bearing rhabdoid tumor xenografts.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765861843367-d66a6e4c-aaa9-4051-8886-73d6bba7d753/assets/EMMM-13-e12640-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765861823499-fc78a7a1-9d6f-4f71-a79f-f4f1699a1b39/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012993</link>
            <description><![CDATA[<p class="para" id="N65542">Antisense oligonucleotide (AO)‐mediated exon‐skipping therapies show promise in Duchenne muscular dystrophy (DMD), a devastating muscular disease caused by frame‐disrupting mutations in the <i>DMD</i> gene. However, insufficient systemic delivery remains a hurdle to clinical deployment. Here, we demonstrate that MOTS‐c, a mitochondria‐derived bioactive peptide, with an intrinsic muscle‐targeting property, augmented glycolytic flux and energy production capacity of dystrophic muscles <i>in vitro</i> and <i>in vivo</i>, resulting in enhanced phosphorodiamidate morpholino oligomer (PMO) uptake and activity in <i>mdx</i> mice. Long‐term repeated administration of MOTS‐c (500 μg) and PMO at the dose of 12.5 mg/kg/week for 3 weeks followed by 12.5 mg/kg/month for 3 months (PMO‐M) induced therapeutic levels of dystrophin expression in peripheral muscles, with up to 25‐fold increase in diaphragm of <i>mdx</i> mice over PMO alone. PMO‐M improved muscle function and pathologies in <i>mdx</i> mice without detectable toxicity. Our results demonstrate that MOTS‐c enables enhanced PMO uptake and activity in dystrophic muscles by providing energy and may have therapeutic implications for exon‐skipping therapeutics in DMD and other energy‐deficient disorders.</p><p class="para" id="N65541">This study demonstrates the use of MOTS‐c peptide to promote oligonucleotides uptake in muscle cells by augmenting glycolytic flux and energy production. This approach may be used to improve the success of DMD exon‐skipping therapy and potentially be used for other diseases with hallmarks of energy deficiency.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765861823499-fc78a7a1-9d6f-4f71-a79f-f4f1699a1b39/assets/EMMM-13-e12993-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[An organoid‐derived bronchioalveolar model for SARS‐CoV‐2 infection of human alveolar type II‐like cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765861738854-8ae2fb15-c824-4a2b-89dc-2b663b9716ee/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105912</link>
            <description><![CDATA[<p class="para" id="N65542">Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) causes coronavirus disease 2019 (COVID‐19), which may result in acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The alveolar epithelium is a major target of the virus, but representative models to study virus host interactions in more detail are currently lacking. Here, we describe a human 2D air–liquid interface culture system which was characterized by confocal and electron microscopy and single‐cell mRNA expression analysis. In this model, alveolar cells, but also basal cells and rare neuroendocrine cells, are grown from 3D self‐renewing fetal lung bud tip organoids. These cultures were readily infected by SARS‐CoV‐2 with mainly surfactant protein C‐positive alveolar type II‐like cells being targeted. Consequently, significant viral titers were detected and mRNA expression analysis revealed induction of type I/III interferon response program. Treatment of these cultures with a low dose of interferon lambda 1 reduced viral replication. Hence, these cultures represent an experimental model for SARS‐CoV‐2 infection and can be applied for drug screens.</p><p class="para" id="N65541">A human airway <i>in vitro</i> culture permissive to COVID‐19 demonstrates a drug‐sensitive IFN response.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765861738854-8ae2fb15-c824-4a2b-89dc-2b663b9716ee/assets/EMBJ-40-e105912-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[MicroRNA‐574 regulates FAM210A expression and influences pathological cardiac remodeling]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765861700635-337b333d-5350-4fd0-84df-f21e2cb59554/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012710</link>
            <description><![CDATA[<p class="para" id="N65542">Aberrant expression of mitochondrial proteins impairs cardiac function and causes heart disease. The mechanism of regulation of mitochondria encoded protein expression during cardiac disease, however, remains underexplored. Here, we show that multiple pathogenic cardiac stressors induce the expression of miR‐574 guide and passenger strands (miR‐574‐5p/3p) in both humans and mice. miR‐574 knockout mice exhibit severe cardiac disorder under different pathogenic cardiac stresses while miR‐574‐5p/3p mimics that are delivered systematically using nanoparticles reduce cardiac pathogenesis under disease insults. Transcriptomic analysis of miR‐574‐null hearts uncovers family with sequence similarity 210 member A (FAM210A) as a common target mRNA of miR‐574‐5p and miR‐574‐3p. The interactome capture analysis suggests that FAM210A interacts with mitochondrial translation elongation factor EF‐Tu. Manipulating miR‐574‐5p/3p or FAM210A expression changes the protein expression of mitochondrial‐encoded electron transport chain (ETC) genes but not nuclear‐encoded mitochondrial ETC genes in both human AC16 cardiomyocyte cells and miR‐574‐null murine hearts. Together, we discovered that miR‐574 regulates FAM210A expression and modulates mitochondrial‐encoded protein expression, which may influence cardiac remodeling in heart failure.</p><p class="para" id="N65541">The findings identify that miR‐574 fine‐tunes FAM210A expression and modulates mitochondrial encoded protein expression, thereby maintaining normal mitochondrial function and protecting the heart from cardiac stress induced pathological remodeling.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765861700635-337b333d-5350-4fd0-84df-f21e2cb59554/assets/EMMM-13-e12710-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Neuron type‐specific increase in lamin B1 contributes to nuclear dysfunction in Huntington’s disease]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765861520036-a678bfe7-b181-40a4-bad2-faf0c928aca4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012105</link>
            <description><![CDATA[<p class="para" id="N65542">Lamins are crucial proteins for nuclear functionality. Here, we provide new evidence showing that increased lamin B1 levels contribute to the pathophysiology of Huntington’s disease (HD), a CAG repeat‐associated neurodegenerative disorder. Through fluorescence‐activated nuclear suspension imaging, we show that nucleus from striatal medium‐sized spiny and CA1 hippocampal neurons display increased lamin B1 levels, in correlation with altered nuclear morphology and nucleocytoplasmic transport disruption. Moreover, ChIP‐sequencing analysis shows an alteration of lamin‐associated chromatin domains in hippocampal nuclei, accompanied by changes in chromatin accessibility and transcriptional dysregulation. Supporting lamin B1 alterations as a causal role in mutant huntingtin‐mediated neurodegeneration, pharmacological normalization of lamin B1 levels in the hippocampus of the R6/1 mouse model of HD by betulinic acid administration restored nuclear homeostasis and prevented motor and cognitive dysfunction. Collectively, our work points increased lamin B1 levels as a new pathogenic mechanism in HD and provides a novel target for its intervention.</p><p class="para" id="N65541">The study shows that increased lamin B1 levels contribute to altered nuclear function of specific neurons in Huntington's disease (HD) brain. Results highlight this alteration as a new pathogenic mechanism for HD and provide a novel target for HD intervention.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765861520036-a678bfe7-b181-40a4-bad2-faf0c928aca4/assets/EMMM-13-e12105-g016.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Modulation of plant root growth by nitrogen source‐defined regulation of polar auxin transport]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765852408172-777b77f7-4533-411a-ba3f-ee2656f1a95c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020106862</link>
            <description><![CDATA[<p class="para" id="N65542">Availability of the essential macronutrient nitrogen in soil plays a critical role in plant growth, development, and impacts agricultural productivity. Plants have evolved different strategies for sensing and responding to heterogeneous nitrogen distribution. Modulation of root system architecture, including primary root growth and branching, is among the most essential plant adaptions to ensure adequate nitrogen acquisition. However, the immediate molecular pathways coordinating the adjustment of root growth in response to distinct nitrogen sources, such as nitrate or ammonium, are poorly understood. Here, we show that growth as manifested by cell division and elongation is synchronized by coordinated auxin flux between two adjacent outer tissue layers of the root. This coordination is achieved by nitrate‐dependent dephosphorylation of the PIN2 auxin efflux carrier at a previously uncharacterized phosphorylation site, leading to subsequent PIN2 lateralization and thereby regulating auxin flow between adjacent tissues. A dynamic computer model based on our experimental data successfully recapitulates experimental observations. Our study provides mechanistic insights broadening our understanding of root growth mechanisms in dynamic environments.</p><p class="para" id="N65541">
<i>Arabidopsis</i> roots adjust their growth to the type of nitrogen source via phosphorylation of auxin carrier PIN2 and adjustment of auxin distribution between neighboring tissues.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765852408172-777b77f7-4533-411a-ba3f-ee2656f1a95c/assets/EMBJ-40-e106862-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Clock component OsPRR73 positively regulates rice salt tolerance by modulating <i>OsHKT2;1</i>‐mediated sodium homeostasis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765851526869-42ea82a7-0ef6-45da-ab9a-8f1a29a1bd31/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105086</link>
            <description><![CDATA[<p class="para" id="N65542">The roles of clock components in salt stress tolerance remain incompletely characterized in rice. Here, we show that, among <i>OsPRR</i> (<i>Oryza sativa Pseudo‐Response Regulator</i>) family members, <i>OsPRR73</i> specifically confers salt tolerance in rice. Notably, the grain size and yield of <i>osprr73</i> null mutants were significantly decreased in the presence of salt stress, with accumulated higher level of reactive oxygen species and sodium ions. RNA sequencing and biochemical assays identified <i>OsHKT2;1</i>, encoding a plasma membrane‐localized Na<sup>+</sup> transporter, as a transcriptional target of OsPRR73 in mediating salt tolerance. Correspondingly, null mutants of <i>OsHKT2;1</i> displayed an increased tolerance to salt stress. Immunoprecipitation‐mass spectrometry (IP‐MS) assays further identified HDAC10 as nuclear interactor of OsPRR73 and co‐repressor of <i>OsHKT2;1</i>. Consistently, H3K9ac histone marks at <i>OsHKT2;1</i> promoter regions were significantly reduced in <i>osprr73</i> mutant. Together, our findings reveal that salt‐induced <i>OsPRR73</i> expression confers salt tolerance by recruiting HDAC10 to transcriptionally repress <i>OsHKT2;1</i>, thus reducing cellular Na<sup>+</sup> accumulation. This exemplifies a new molecular link between clock components and salt stress tolerance in rice.</p><p class="para" id="N65541">A member of the pseudo response regulator (PRR) family in rice is induced upon salt stress to decrease expression of a sodium transporter via chromatin modifications.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765851526869-42ea82a7-0ef6-45da-ab9a-8f1a29a1bd31/assets/EMBJ-40-e105086-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A new linear cyclin docking motif that mediates exclusively S‐phase CDK‐specific signaling]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765846930040-3da4bd50-0426-49da-99e4-99583c2f03ce/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105839</link>
            <description><![CDATA[<p class="para" id="N65542">Cyclin‐dependent kinases (CDKs), the master regulators of cell division, are activated by different cyclins at different cell cycle stages. In addition to being activators of CDKs, cyclins recognize various linear motifs to target CDK activity to specific proteins. We uncovered a cyclin docking motif, NLxxxL, that contributes to phosphorylation‐dependent degradation of the CDK inhibitor Far1 at the G1/S stage in the yeast <i>Saccharomyces cerevisiae</i>. This motif is recognized exclusively by S‐phase CDK (S‐CDK) Clb5/6‐Cdc28 and is considerably more potent than the conventional RxL docking motif. The NLxxxL and RxL motifs were found to overlap in some target proteins, suggesting that cyclin docking motifs can evolve to switch from one to another for fine‐tuning of cell cycle events. Using time‐lapse fluorescence microscopy, we show how different docking connections temporally control phosphorylation‐driven target degradation. This also revealed a differential function of the phosphoadaptor protein Cks1, as Cks1 docking potentiated degron phosphorylation of RxL‐containing but not of NLxxxL‐containing substrates. The NLxxxL motif was found to govern S‐cyclin‐specificity in multiple yeast CDK targets including Fin1, Lif1, and Slx4, suggesting its wider importance.</p><p class="para" id="N65541">The short linear motif NLxxxl present in several yeast cyclin‐dependent kinase substrates like Far1 and Slx4 targets them specifically to Clb5‐Cdk1 complexes active in S‐phase.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765846930040-3da4bd50-0426-49da-99e4-99583c2f03ce/assets/EMBJ-40-e105839-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Netrin‐1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson’s disease features]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765821760248-0edee592-d0d3-41a6-931f-93b3beaba081/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105537</link>
            <description><![CDATA[<p class="para" id="N65542">The netrin‐1/DCC ligand/receptor pair has key roles in central nervous system (CNS) development, mediating axonal, and neuronal navigation. Although expression of netrin‐1 and DCC is maintained in the adult brain, little is known about their role in mature neurons. Notably, netrin‐1 is highly expressed in the adult substantia nigra, leading us to investigate a role of the netrin‐1/DCC pair in adult nigral neuron fate. Here, we show that silencing netrin‐1 in the adult substantia nigra of mice induces DCC cleavage and a significant loss of dopamine neurons, resulting in motor deficits. Because loss of adult dopamine neurons and motor impairments are features of Parkinson’s disease (PD), we studied the potential impact of netrin‐1 in different animal models of PD. We demonstrate that both overexpression of netrin‐1 and brain administration of recombinant netrin‐1 are neuroprotective and neurorestorative in mouse and rat models of PD. Of interest, we observed that netrin‐1 levels are significantly reduced in PD patient brain samples. These results highlight the key role of netrin‐1 in adult dopamine neuron fate, and the therapeutic potential of targeting netrin‐1 signaling in PD.</p><p class="para" id="N65541">
<i>In vivo</i> silencing reveals a pro‐survival role for the developmental axon guidance cue netrin‐1 in the adult mouse substantia nigra, which may be lost in Parkinson's patients and thus offering potential therapeutic options.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765821760248-0edee592-d0d3-41a6-931f-93b3beaba081/assets/EMBJ-40-e105537-g008.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of <i>ALK</i> mutation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820757381-a97528e4-9602-463f-879b-f1000b1c043f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105784</link>
            <description><![CDATA[<p class="para" id="N65542">High‐risk neuroblastoma (NB) is responsible for a disproportionate number of childhood deaths due to cancer. One indicator of high‐risk NB is amplification of the neural <i>MYC</i> (<i>MYCN</i>) oncogene, which is currently therapeutically intractable. Identification of anaplastic lymphoma kinase (ALK) as an NB oncogene raised the possibility of using ALK tyrosine kinase inhibitors (TKIs) in treatment of patients with activating ALK mutations. 8–10% of primary NB patients are ALK‐positive, a figure that increases in the relapsed population. ALK is activated by the ALKAL2 ligand located on chromosome 2p, along with <i>ALK</i> and <i>MYCN</i>, in the “2p‐gain” region associated with NB. Dysregulation of ALK ligand in NB has not been addressed, although one of the first oncogenes described was <i>v‐sis</i> that shares &gt; 90% homology with PDGF. Therefore, we tested whether ALKAL2 ligand could potentiate NB progression in the absence of ALK mutation. We show that ALKAL2 overexpression in mice drives ALK TKI‐sensitive NB in the absence of ALK mutation, suggesting that additional NB patients, such as those exhibiting 2p‐gain, may benefit from ALK TKI‐based therapeutic intervention.</p><p class="para" id="N65541">ALKAL2 misregulation facilitates ALK receptor tyrosine kinase signaling and drives ALK‐dependent cancer irrespective of oncogenic mutations.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765820757381-a97528e4-9602-463f-879b-f1000b1c043f/assets/EMBJ-40-e105784-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Tyrosine phosphorylation regulates hnRNPA2 granule protein partitioning and reduces neurodegeneration]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820700376-06ba7289-044c-4bc5-9a76-97ce428286e3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105001</link>
            <description><![CDATA[<p class="para" id="N65542">mRNA transport in neurons requires formation of transport granules containing many protein components, and subsequent alterations in phosphorylation status can release transcripts for translation. Further, mutations in a structurally disordered domain of the transport granule protein hnRNPA2 increase its aggregation and cause hereditary proteinopathy of neurons, myocytes, and bone. We examine <i>in vitro</i> hnRNPA2 granule component phase separation, partitioning specificity, assembly/disassembly, and the link to neurodegeneration. Transport granule components hnRNPF and ch‐TOG interact weakly with hnRNPA2 yet partition specifically into liquid phase droplets with the low complexity domain (LC) of hnRNPA2, but not FUS LC. <i>In vitro</i> hnRNPA2 tyrosine phosphorylation reduces hnRNPA2 phase separation, prevents partitioning of hnRNPF and ch‐TOG into hnRNPA2 LC droplets, and decreases aggregation of hnRNPA2 disease variants. The expression of chimeric hnRNPA2 D290V in <i>Caenorhabditis elegans</i> results in stress‐induced glutamatergic neurodegeneration; this neurodegeneration is rescued by loss of <i>tdp‐1,</i> suggesting gain‐of‐function toxicity. The expression of Fyn, a tyrosine kinase that phosphorylates hnRNPA2, reduces neurodegeneration associated with chimeric hnRNPA2 D290V. These data suggest a model where phosphorylation alters LC interaction specificity, aggregation, and toxicity.</p><p class="para" id="N65541">Combination of NMR, <i>in vitro</i> and <i>in vivo</i> assays reveal that phosphorylation of the RNA binding protein hnRNPA2, linked to protein aggregation diseases and a component of transport granules, reduces liquid‐liquid phase separation and protein aggregation pointing to new strategies for the treatment of neurodegenerative diseases.
<div class="section"><div class="box" id="N65549"><div class="imageVideo"><img src="/dataresources/secured/content-1765820700376-06ba7289-044c-4bc5-9a76-97ce428286e3/assets/EMBJ-40-e105001-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SATB2‐LEMD2 interaction links nuclear shape plasticity to regulation of cognition‐related genes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820024129-5a700e20-a615-4ba7-a26b-039423c76731/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2019103701</link>
            <description><![CDATA[<p class="para" id="N65542">
<i>SATB2</i> is a schizophrenia risk gene and is genetically associated with human intelligence. How it affects cognition at molecular level is currently unknown. Here, we show that interactions between SATB2, a chromosomal scaffolding protein, and the inner nuclear membrane protein LEMD2 orchestrate the response of pyramidal neurons to neuronal activation. Exposure to novel environment <i>in vivo</i> causes changes in nuclear shape of CA1 hippocampal neurons via a SATB2‐dependent mechanism. The activity‐driven plasticity of the nuclear envelope requires not only SATB2, but also its protein interactor LEMD2 and the ESCRT‐III/VPS4 membrane‐remodeling complex. Furthermore, LEMD2 depletion in cortical neurons, similar to SATB2 ablation, affects neuronal activity‐dependent regulation of multiple rapid and delayed primary response genes. In human genetic data, LEMD2‐regulated genes are enriched for <i>de novo</i> mutations reported in intellectual disability and schizophrenia and are, like SATB2‐regulated genes, enriched for common variants associated with schizophrenia and cognitive function. Hence, interactions between SATB2 and the inner nuclear membrane protein LEMD2 influence gene expression programs in pyramidal neurons that are linked to cognitive ability and psychiatric disorder etiology.</p><p class="para" id="N65541">In cortical neurons, a chromosomal scaffold protein and an inner nuclear membrane protein orchestrate activity‐dependent nuclear shape changes and transcription of genes associated with cognitive function.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765820024129-5a700e20-a615-4ba7-a26b-039423c76731/assets/EMBJ-40-e103701-g012.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Intrinsically disordered protein PID‐2 modulates Z granules and is required for heritable piRNA‐induced silencing in the <i>Caenorhabditis elegans</i> embryo]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765819908618-a15639c8-f30f-445e-94a8-c375c4699742/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105280</link>
            <description><![CDATA[<p class="para" id="N65542">In <i>Caenorhabditis elegans</i>, the piRNA (21U RNA) pathway is required to establish proper gene regulation and an immortal germline. To achieve this, PRG‐1‐bound 21U RNAs trigger silencing mechanisms mediated by RNA‐dependent RNA polymerase (RdRP)‐synthetized 22G RNAs. This silencing can become PRG‐1‐independent and heritable over many generations, a state termed RNA‐induced epigenetic gene silencing (RNAe). How and when RNAe is established, and how it is maintained, is not known. We show that maternally provided 21U RNAs can be sufficient for triggering RNAe in embryos. Additionally, we identify PID‐2, a protein containing intrinsically disordered regions (IDRs), as a factor required for establishing and maintaining RNAe. PID‐2 interacts with two newly identified and partially redundant eTudor domain‐containing proteins, PID‐4 and PID‐5. PID‐5 has an additional domain related to the X‐prolyl aminopeptidase APP‐1, and binds APP‐1, implicating potential N‐terminal proteolysis in RNAe. All three proteins are required for germline immortality, localize to perinuclear foci, affect size and appearance of RNA inheritance‐linked Z granules, and are required for balancing of 22G RNA populations. Overall, our study identifies three new proteins with crucial functions in <i>C. elegans</i> small RNA silencing.</p><p class="para" id="N65541">PID‐2 and its newly‐identified interactors PID‐4 and PID‐5 modulate size and appearance of Z granules to establish and maintain stable heritable silencing (RNAe) by maternal piRNAs.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765819908618-a15639c8-f30f-445e-94a8-c375c4699742/assets/EMBJ-40-e105280-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-24T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Lamin B1 decline underlies age‐related loss of adult hippocampal neurogenesis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765819681236-dfdc6d26-0424-4496-8a64-82613777a1ea/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105819</link>
            <description><![CDATA[<p class="para" id="N65542">Neurogenesis in the adult hippocampus declines with age, a process that has been implicated in cognitive and emotional impairments. However, the mechanisms underlying this decline have remained elusive. Here, we show that the age‐dependent downregulation of lamin B1, one of the nuclear lamins in adult neural stem/progenitor cells (ANSPCs), underlies age‐related alterations in adult hippocampal neurogenesis. Our results indicate that higher levels of lamin B1 in ANSPCs safeguard against premature differentiation and regulate the maintenance of ANSPCs. However, the level of lamin B1 in ANSPCs declines during aging. Precocious loss of lamin B1 in ANSPCs transiently promotes neurogenesis but eventually depletes it. Furthermore, the reduction of lamin B1 in ANSPCs recapitulates age‐related anxiety‐like behavior in mice. Our results indicate that the decline in lamin B1 underlies stem cell aging and impacts the homeostasis of adult neurogenesis and mood regulation.</p><p class="para" id="N65541">Ablation of the nuclear envelope protein lamin B1 in neural stem/progenitor cells disrupts neurogenesis and causes aging‐associated behavioral changes in mice.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765819681236-dfdc6d26-0424-4496-8a64-82613777a1ea/assets/EMBJ-40-e105819-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Translation is required for miRNA‐dependent decay of endogenous transcripts]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765817965918-667ce724-1801-44a1-8032-ad7f6e3053d7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104569</link>
            <description><![CDATA[<p class="para" id="N65542">Post‐transcriptional repression of gene expression by miRNAs occurs through transcript destabilization or translation inhibition. mRNA decay is known to account for most miRNA‐dependent repression. However, because transcript decay occurs co‐translationally, whether target translation is a requirement for miRNA‐dependent transcript destabilization remains unknown. To decouple these two molecular processes, we used cytosolic long noncoding RNAs (lncRNAs) as models for endogenous transcripts that are not translated. We show that, despite interacting with the miRNA‐loaded RNA‐induced silencing complex, the steady‐state abundance and decay rates of these transcripts are minimally affected by miRNA loss. To further validate the apparent requirement of translation for miRNA‐dependent decay, we fused two lncRNA candidates to the 3’‐end of a protein‐coding gene reporter and found this results in their miRNA‐dependent destabilization. Further analysis revealed that the few natural lncRNAs whose levels are regulated by miRNAs in mESCs tend to associate with translating ribosomes, and possibly represent misannotated micropeptides, further substantiating the necessity of target translation for miRNA‐dependent transcript decay. In summary, our analyses suggest that translation is required for miRNA‐dependent transcript destabilization, and demonstrate that the levels of coding and noncoding transcripts are differently affected by miRNAs.</p><p class="para" id="N65541">Real lncRNAs are bound, but not degraded by miRNA‐loaded RNA‐induced silencing complexes, establishing different susceptibilities of coding and non‐coding RNA to miRNA‐dependent repression.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765817965918-667ce724-1801-44a1-8032-ad7f6e3053d7/assets/EMBJ-40-e104569-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A microtubule‐LUZP1 association around tight junction promotes epithelial cell apical constriction]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765789771481-4ada157b-8dc8-48ec-9fa9-457ff0148f4f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104712</link>
            <description><![CDATA[<p class="para" id="N65542">Apical constriction is critical for epithelial morphogenesis, including neural tube formation. Vertebrate apical constriction is induced by di‐phosphorylated myosin light chain (ppMLC)‐driven contraction of actomyosin‐based circumferential rings (CRs), also known as perijunctional actomyosin rings, around apical junctional complexes (AJCs), mainly consisting of tight junctions (TJs) and adherens junctions (AJs). Here, we revealed a ppMLC‐triggered system at TJ‐associated CRs for vertebrate apical constriction involving microtubules, LUZP1, and myosin phosphatase. We first identified LUZP1 via unbiased screening of microtubule‐associated proteins in the AJC‐enriched fraction. In cultured epithelial cells, LUZP1 was found localized at TJ‐, but not at AJ‐, associated CRs, and LUZP1 knockout resulted in apical constriction defects with a significant reduction in ppMLC levels within CRs. A series of assays revealed that ppMLC promotes the recruitment of LUZP1 to TJ‐associated CRs, where LUZP1 spatiotemporally inhibits myosin phosphatase in a microtubule‐facilitated manner. Our results uncovered a hitherto unknown microtubule‐LUZP1 association at TJ‐associated CRs that inhibits myosin phosphatase, contributing significantly to the understanding of vertebrate apical constriction.</p><p class="para" id="N65541">The neural tube‐closure regulator LUZP1 drives apical constriction of epithelial cells by inhibiting myosin phosphatase activity in a microtubule‐dependent manner<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765789771481-4ada157b-8dc8-48ec-9fa9-457ff0148f4f/assets/EMBJ-40-e104712-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Cell softness regulates tumorigenicity and stemness of cancer cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765789561287-dcdc120c-1d22-4307-bce1-674425865b58/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020106123</link>
            <description><![CDATA[<p class="para" id="N65542">Identifying and sorting highly tumorigenic and metastatic tumor cells from a heterogeneous cell population is a daunting challenge. Here, we show that microfluidic devices can be used to sort marker‐based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations. The isolated soft tumor cells (&lt; 400 Pa) but not the stiff ones (&gt; 700 Pa) can form a tumor in immunocompetent mice with 100 cells per inoculation. Notably, only the soft, but not the stiff cells, isolated from CD133<sup>+</sup>, ALDH<sup>+</sup>, or side population CSCs, are able to form a tumor with only 100 cells in NOD‐SCID or immunocompetent mice. The Wnt signaling protein BCL9L is upregulated in soft tumor cells and regulates their stemness and tumorigenicity. Clinically, BCL9L expression is correlated with a worse prognosis. Our findings suggest that the intrinsic softness is a unique marker of highly tumorigenic and metastatic tumor cells.</p><p class="para" id="N65541">Intrinsic mechanical properties and BCL9L expression in tumor cells determine their stemness and are linked to cancer progression.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765789561287-dcdc120c-1d22-4307-bce1-674425865b58/assets/EMBJ-40-e106123-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Pharmacological reversal of synaptic and network pathology in human <i>MECP2</i>‐KO neurons and cortical organoids]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769370394-2ef31879-6b0f-4885-8306-299d749815ac/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012523</link>
            <description><![CDATA[<p class="para" id="N65542">Duplication or deficiency of the X‐linked <i>MECP2</i> gene reliably produces profound neurodevelopmental impairment. <i>MECP2</i> mutations are almost universally responsible for Rett syndrome (RTT), and particular mutations and cellular mosaicism of <i>MECP2</i> may underlie the spectrum of RTT symptomatic severity. No clinically approved treatments for RTT are currently available, but human pluripotent stem cell technology offers a platform to identify neuropathology and test candidate therapeutics. Using a strategic series of increasingly complex human stem cell‐derived technologies, including human neurons, <i>MECP2</i>‐mosaic neurospheres to model RTT female brain mosaicism, and cortical organoids, we identified synaptic dysregulation downstream from knockout of <i>MECP2</i> and screened select pharmacological compounds for their ability to treat this dysfunction. Two lead compounds, Nefiracetam and PHA 543613, specifically reversed <i>MECP2‐</i>knockout cytologic neuropathology. The capacity of these compounds to reverse neuropathologic phenotypes and networks in human models supports clinical studies for neurodevelopmental disorders in which MeCP2 deficiency is the predominant etiology.</p><p class="para" id="N65541">Deficiency of the X‐linked <i>MECP2</i> gene profoundly impairs neurodevelopment. Clinically, mutations in <i>MECP2</i> most commonly present as the severe and untreatable disease Rett syndrome. Innovative human pluripotent stem cell (PSC) technology enables the investigation of therapeutic candidates.
<div class="section"><div class="box" id="N65549"><div class="imageVideo"><img src="/dataresources/secured/content-1765769370394-2ef31879-6b0f-4885-8306-299d749815ac/assets/EMMM-13-e12523-g012.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant <i>Mycobacterium tuberculosis</i>
]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769351676-bf47cd10-117d-46a5-90cf-55c513f4b7e5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202013207</link>
            <description><![CDATA[<p class="para" id="N65542">The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F<sub>1</sub>F<sub>0</sub> ATP synthase, small molecules targeting other components of the oxidative phosphorylation pathway have been identified. Of particular interest is Telacebec (Q203), a phase 2 drug candidate inhibitor of the cytochrome <i>bcc:aa<sub>3</sub></i> terminal oxidase. A functional redundancy between the cytochrome <i>bcc:aa<sub>3</sub></i> and the cytochrome <i>bd</i> oxidase protects <i>M</i>.<i> tuberculosis</i> from Q203‐induced death, highlighting the attractiveness of the <i>bd</i>‐type terminal oxidase for drug development. Here, we employed a facile whole‐cell screen approach to identify the cytochrome <i>bd</i> inhibitor ND‐011992. Although ND‐011992 is ineffective on its own, it inhibits respiration and ATP homeostasis in combination with Q203. The drug combination was bactericidal against replicating and antibiotic‐tolerant, non‐replicating mycobacteria, and increased efficacy relative to that of a single drug in a mouse model. These findings suggest that a cytochrome <i>bd</i> oxidase inhibitor will add value to a drug combination targeting oxidative phosphorylation for tuberculosis treatment.</p><p class="para" id="N65541">The functional redundancy of two terminal oxidases in mycobacteria limits the efficacy of phase 2 clinical candidate Telacebec (Q203). In this study we identified a cytochrome bd oxidase inhibitor ND‐011992 that together with Q203 forms a bactericidal drug combination against <i>Mycobacterium tuberculosis</i>.
<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765769351676-bf47cd10-117d-46a5-90cf-55c513f4b7e5/assets/EMMM-13-e13207-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeted stabilization of Munc18‐1 function via pharmacological chaperones]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769295817-cac39837-9484-4400-a413-b05280a19d9a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012354</link>
            <description><![CDATA[<p class="para" id="N65542">Heterozygous <i>de novo</i> mutations in the neuronal protein Munc18‐1 cause syndromic neurological symptoms, including severe epilepsy, intellectual disability, developmental delay, ataxia, and tremor. No disease‐modifying therapy exists to treat these disorders, and while chemical chaperones have been shown to alleviate neuronal dysfunction caused by missense mutations in Munc18‐1, their required high concentrations and potential toxicity necessitate a Munc18‐1‐targeted therapy. Munc18‐1 is essential for neurotransmitter release, and mutations in Munc18‐1 have been shown to cause neuronal dysfunction via aggregation and co‐aggregation of the wild‐type protein, reducing functional Munc18‐1 levels well below hemizygous levels. Here, we identify two pharmacological chaperones via structure‐based drug design, that bind to wild‐type and mutant Munc18‐1, and revert Munc18‐1 aggregation and neuronal dysfunction <i>in vitro</i> and <i>in vivo</i>, providing the first targeted treatment strategy for these severe pediatric encephalopathies.</p><p class="para" id="N65541">This study presents a novel treatment strategy for the severe epileptic encephalopathies associated with Munc18‐1 mutations. Using an <i>in silico</i> screen followed by validations in mouse neurons and <i>C. elegans</i> models, three compounds that target Munc18‐1 and reverse neuronal dysfunction are identified.
<div class="section"><div class="box" id="N65549"><div class="imageVideo"><img src="/dataresources/secured/content-1765769295817-cac39837-9484-4400-a413-b05280a19d9a/assets/EMMM-13-e12354-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769208124-f88e527c-31cb-4106-a6a3-35a9699bbe6a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012798</link>
            <description><![CDATA[<p class="para" id="N65542">Immune checkpoint blockade (ICB) has a limited effect on colorectal cancer, underlining the requirement of co‐targeting the complementary mechanisms. Here, we identified prostaglandin E2 (PGE<sub>2</sub>) receptor 4 (EP4) as the master regulator of immunosuppressive myeloid cells (IMCs), which are the major driver of resistance to ICB therapy. PGE<sub>2</sub>‐bound EP4 promotes the differentiation of immunosuppressive M2 macrophages and myeloid‐derived suppressor cells (MDSCs) and reduces the expansion of immunostimulated M1 macrophages. To explore the immunotherapeutic role of EP4 signaling, we developed a novel and selective EP4 antagonist TP‐16. TP‐16 effectively blocked the function of IMCs and enhanced cytotoxic T‐cell‐mediated tumor elimination <i>in vivo</i>. Cell co‐culture experiments revealed that TP‐16 promoted T‐cell proliferation, which was impaired by tumor‐derived CD11b<sup>+</sup> myeloid cells. Notably, TP‐16 and anti‐PD‐1 combination therapy significantly impeded tumor progression and prolonged mice survival. We further demonstrated that TP‐16 increased responsiveness to anti‐PD‐1 therapy in an IMC‐related spontaneous colorectal cancer mouse model. In summary, this study demonstrates that inhibition of EP4‐expressing IMCs may offer a potential strategy for enhancing the efficacy of immunotherapy for colorectal cancer.</p><p class="para" id="N65541">Immunosuppressive myeloid cells (IMCs) are a prominent driver of immunotherapy resistance in colorectal cancer. This study identifies EP4 as a master regulator of IMCs and highlights blockade of EP4 as a novel therapeutic strategy for enhancing immunotherapy in colorectal cancer.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765769208124-f88e527c-31cb-4106-a6a3-35a9699bbe6a/assets/EMMM-13-e12798-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769181041-94afc719-2f9c-46df-8025-a85cb054fdbe/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012828</link>
            <description><![CDATA[<p class="para" id="N65542">To circumvent the devastating pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, a humanized decoy antibody (ACE2‐Fc fusion protein) was designed to target the interaction between viral spike protein and its cellular receptor, angiotensin‐converting enzyme 2 (ACE2). First, we demonstrated that ACE2‐Fc could specifically abrogate virus replication by blocking the entry of SARS‐CoV‐2 spike‐expressing pseudotyped virus into both ACE2‐expressing lung cells and lung organoids. The impairment of viral entry was not affected by virus variants, since efficient inhibition was also observed in six SARS‐CoV‐2 clinical strains, including the D614G variants which have been shown to exhibit increased infectivity. The preservation of peptidase activity also enables ACE2‐Fc to reduce the angiotensin II‐mediated cytokine cascade. Furthermore, this Fc domain of ACE2‐Fc was shown to activate NK cell degranulation after co‐incubation with Spike‐expressing H1975 cells. These promising characteristics potentiate the therapeutic prospects of ACE2‐Fc as an effective treatment for COVID‐19.</p><p class="para" id="N65541">Currently, there is no effective strategy to fight against the COVID‐19 pandemic. We aim to design and develop a humanized decoy antibody to block SARS‐CoV‐2 infection.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765769181041-94afc719-2f9c-46df-8025-a85cb054fdbe/assets/EMMM-13-e12828-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A novel P2X2‐dependent purinergic mechanism of enteric gliosis in intestinal inflammation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769154880-1d1f8a1d-e388-4e53-9755-a4a2fa7edb99/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012724</link>
            <description><![CDATA[<p class="para" id="N65542">Enteric glial cells (EGC) modulate motility, maintain gut homeostasis, and contribute to neuroinflammation in intestinal diseases and motility disorders. Damage induces a reactive glial phenotype known as “gliosis”, but the molecular identity of the inducing mechanism and triggers of “enteric gliosis” are poorly understood. We tested the hypothesis that surgical trauma during intestinal surgery triggers ATP release that drives enteric gliosis and inflammation leading to impaired motility in postoperative ileus (POI). ATP activation of a p38‐dependent MAPK pathway triggers cytokine release and a gliosis phenotype in murine (and human) EGCs. Receptor antagonism and genetic depletion studies revealed P2X2 as the relevant ATP receptor and pharmacological screenings identified ambroxol as a novel P2X2 antagonist. Ambroxol prevented ATP‐induced enteric gliosis, inflammation, and protected against dysmotility, while abrogating enteric gliosis in human intestine exposed to surgical trauma. We identified a novel pathogenic P2X2‐dependent pathway of ATP‐induced enteric gliosis, inflammation and dysmotility in humans and mice. Interventions that block enteric glial P2X2 receptors during trauma may represent a novel therapy in treating POI and immune‐driven intestinal motility disorders.</p><p class="para" id="N65541">Enteric gliosis was shown to be part of an intestinal immune response upon abdominal surgery. ATP activates enteric glial cells via selective purinergic receptor signalling in mice and humans. Inhibition of this pathogenic pathway by the newly identified P2X2 antagonist ambroxol blocks ATP‐induced enteric gliosis and protects against postoperative ileus.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765769154880-1d1f8a1d-e388-4e53-9755-a4a2fa7edb99/assets/EMMM-13-e12724-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769144963-93886466-0459-4fd4-ad15-541c6c954fa6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012595</link>
            <description><![CDATA[<p class="para" id="N65542">Amyotrophic lateral sclerosis (ALS) is a multi‐system disease characterized primarily by progressive muscle weakness. Cognitive dysfunction is commonly observed in patients; however, factors influencing risk for cognitive dysfunction remain elusive. Using sparse canonical correlation analysis (sCCA), an unsupervised machine‐learning technique, we observed that single nucleotide polymorphisms collectively associate with baseline cognitive performance in a large ALS patient cohort (<i>N</i> = 327) from the multicenter Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. We demonstrate that a polygenic risk score derived using sCCA relates to longitudinal cognitive decline in the same cohort and also to <i>in vivo</i> cortical thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal cortex, premotor cortex, and hippocampus (<i>N</i> = 90) as well as <i>post‐mortem</i> motor cortical neuronal loss (<i>N</i> = 87) in independent ALS cohorts from the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our findings suggest that common genetic polymorphisms may exert a polygenic contribution to the risk of cortical disease vulnerability and cognitive dysfunction in ALS.</p><p class="para" id="N65541">Single nucleotide polymorphisms (SNPs) previously identified through genome‐wide association studies as risk factors for amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) further associate in a polygenic manner with risk for cognitive dysfunction in ALS and related disorders.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765769144963-93886466-0459-4fd4-ad15-541c6c954fa6/assets/EMMM-13-e12595-g011.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Improvement of islet transplantation by the fusion of islet cells with functional blood vessels]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765769027211-845895c4-0338-4c74-a0e8-35cc36961a65/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/emmm.202012616</link>
            <description><![CDATA[<p class="para" id="N65542">Pancreatic islet transplantation still represents a promising therapeutic strategy for curative treatment of type 1 diabetes mellitus. However, a limited number of organ donors and insufficient vascularization with islet engraftment failure restrict the successful transfer of this approach into clinical practice. To overcome these problems, we herein introduce a novel strategy for the generation of prevascularized islet organoids by the fusion of pancreatic islet cells with functional native microvessels. These insulin‐secreting organoids exhibit a significantly higher angiogenic activity compared to freshly isolated islets, cultured islets, and non‐prevascularized islet organoids. This is caused by paracrine signaling between the β‐cells and the microvessels, mediated by insulin binding to its corresponding receptor on endothelial cells. <i>In vivo</i>, the prevascularized islet organoids are rapidly blood‐perfused after transplantation by the interconnection of their autochthonous microvasculature with surrounding blood vessels. As a consequence, a lower number of islet grafts are required to restore normoglycemia in diabetic mice. Thus, prevascularized islet organoids may be used to improve the success rates of clinical islet transplantation.</p><p class="para" id="N65541">This study introduces a novel strategy to accelerate the revascularization of transplanted islets by the fusion of microvascular fragments (MVF) with pancreatic islet cells. These prevascularized islet organoids may be used to improve the success rate of clinical islet transplantation.
<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765769027211-845895c4-0338-4c74-a0e8-35cc36961a65/assets/EMMM-13-e12616-g015.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Structures of IS<i>C</i>
<i>th4</i> transpososomes reveal the role of asymmetry in copy‐out/paste‐in DNA transposition]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765747099203-1c2ddc8c-de1a-4816-9930-fb8a4d0f5b95/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105666</link>
            <description><![CDATA[<p class="para" id="N65542">Copy‐out/paste‐in transposition is a major bacterial DNA mobility pathway. It contributes significantly to the emergence of antibiotic resistance, often by upregulating expression of downstream genes upon integration. Unlike other transposition pathways, it requires both asymmetric and symmetric strand transfer steps. Here, we report the first structural study of a copy‐out/paste‐in transposase and demonstrate its ability to catalyze all pathway steps <i>in vitro</i>. X‐ray structures of IS<i>C</i>
<i>th4</i> transposase, a member of the IS
<i>256</i> family of insertion sequences, bound to DNA substrates corresponding to three sequential steps in the reaction reveal an unusual asymmetric dimeric transpososome. During transposition, an array of N‐terminal domains binds a single transposon end while the catalytic domain moves to accommodate the varying substrates. These conformational changes control the path of DNA flanking the transposon end and the generation of DNA‐binding sites. Our results explain the asymmetric outcome of the initial strand transfer and show how DNA binding is modulated by the asymmetric transposase to allow the capture of a second transposon end and to integrate a circular intermediate.</p><p class="para" id="N65541">Structures of IS<i>C</i>
<i>th4</i> transposase/DNA complexes at different stages of the transposition pathway provide first insight into transpososome architecture and reaction mechanism of this major bacterial DNA mobility pathway.
<div class="section"><div class="box" id="N65563"><div class="imageVideo"><img src="/dataresources/secured/content-1765747099203-1c2ddc8c-de1a-4816-9930-fb8a4d0f5b95/assets/EMBJ-40-e105666-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-10-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Clustering and reverse transcription of HIV‐1 genomes in nuclear niches of macrophages]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765746250478-2654d669-7d8e-49e1-b96a-740b49c40f9b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105247</link>
            <description><![CDATA[<p class="para" id="N65542">In order to replicate, human immunodeficiency virus (HIV‐1) reverse‐transcribes its RNA genome into DNA, which subsequently integrates into host cell chromosomes. These two key events of the viral life cycle are commonly viewed as separate not only in time, but also in cellular space, since reverse transcription (RT) is thought to be completed in the cytoplasm before nuclear import and integration. However, the spatiotemporal organization of the early viral replication cycle in macrophages, the natural non‐dividing target cells that constitute reservoirs of HIV‐1 and an obstacle to curing AIDS, remains unclear. Here, we demonstrate that infected macrophages display large nuclear foci of viral DNA (vDNA) and viral RNA, in which multiple viral genomes cluster together. These clusters form in the absence of chromosomal integration, sequester the paraspeckle protein CPSF6, and localize to nuclear speckles. Surprisingly, these viral RNA clusters consist mostly of genomic, incoming RNA, both in cells where reverse transcription is pharmacologically suppressed and in untreated cells. We demonstrate that following temporary inhibition, reverse transcription can resume in the nucleus and lead to vDNA accumulation in these clusters. We further show that nuclear reverse transcription can result in transcription‐competent viral DNA. These findings change our understanding of the early HIV‐1 replication cycle and may have implications for addressing HIV‐1 persistence.</p><p class="para" id="N65541">Imaging of the early viral replication cycle reveals that conversion of incoming viral DNA into DNA can occur inside target cell nuclei, challenging the prevalent notion that HIV‐1 genome reverse transcription and host chromosomal integration are spatiotemporally separate.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765746250478-2654d669-7d8e-49e1-b96a-740b49c40f9b/assets/EMBJ-40-e105247-g013.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-12-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The high‐energy transition state of the glutamate transporter homologue GltPh]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765746242640-2bfe0080-3519-4857-8697-d8e5115dec8e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105415</link>
            <description><![CDATA[<p class="para" id="N65542">Membrane transporters mediate cellular uptake of nutrients, signaling molecules, and drugs. Their overall mechanisms are often well understood, but the structural features setting their rates are mostly unknown. Earlier single‐molecule fluorescence imaging of the archaeal model glutamate transporter homologue Glt<sub>Ph</sub> from Pyrococcus horikoshii suggested that the slow conformational transition from the outward‐ to the inward‐facing state, when the bound substrate is translocated from the extracellular to the cytoplasmic side of the membrane, is rate limiting to transport. Here, we provide insight into the structure of the high‐energy transition state of Glt<sub>Ph</sub> that limits the rate of the substrate translocation process. Using bioinformatics, we identified Glt<sub>Ph</sub> gain‐of‐function mutations in the flexible helical hairpin domain HP2 and applied linear free energy relationship analysis to infer that the transition state structurally resembles the inward‐facing conformation. Based on these analyses, we propose an approach to search for allosteric modulators for transporters.</p><p class="para" id="N65541">Kinetic and mutational studies show that reaching the inward‐facing configuration is rate‐limiting during the archaeal aspartic acid transport cycle.<div class="section"><div class="box" id="N65543"><div class="imageVideo"><img src="/dataresources/secured/content-1765746242640-2bfe0080-3519-4857-8697-d8e5115dec8e/assets/EMBJ-40-e105415-g009.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-13T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Condensin minimizes topoisomerase II‐mediated entanglements of DNA <i>in vivo</i>
]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765745838699-83151ec2-14c7-492d-9bb7-b300cd5f8cd8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020105393</link>
            <description><![CDATA[<p class="para" id="N65542">The juxtaposition of intracellular DNA segments, together with the DNA‐passage activity of topoisomerase II, leads to the formation of DNA knots and interlinks, which jeopardize chromatin structure and gene expression. Recent studies in budding yeast have shown that some mechanism minimizes the knotting probability of intracellular DNA. Here, we tested whether this is achieved via the intrinsic capacity of topoisomerase II for simplifying the equilibrium topology of DNA; or whether it is mediated by SMC (structural maintenance of chromosomes) protein complexes like condensin or cohesin, whose capacity to extrude DNA loops could enforce dissolution of DNA knots by topoisomerase II. We show that the low knotting probability of DNA does not depend on the simplification capacity of topoisomerase II nor on the activities of cohesin or Smc5/6 complexes. However, inactivation of condensin increases the occurrence of DNA knots throughout the cell cycle. These results suggest an <i>in vivo</i> role for the DNA loop extrusion activity of condensin and may explain why condensin disruption produces a variety of alterations in interphase chromatin, in addition to persistent sister chromatid interlinks in mitotic chromatin.</p><p class="para" id="N65541">Preventing knotting and interlinking of juxtaposed DNA segments requires yeast condensin but not cohesin or Smc5/6 complexes, suggesting an <i>in vivo</i> role for the DNA loop‐extrusion activity of this particular SMC protein complex.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765745838699-83151ec2-14c7-492d-9bb7-b300cd5f8cd8/assets/EMBJ-40-e105393-g014.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Flavonol‐mediated stabilization of PIN efflux complexes regulates polar auxin transport]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765744809254-b715faca-e7e5-4507-9316-dcb78451dcf1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.15252/embj.2020104416</link>
            <description><![CDATA[<p class="para" id="N65542">The transport of auxin controls the rate, direction and localization of plant growth and development. The course of auxin transport is defined by the polar subcellular localization of the PIN proteins, a family of auxin efflux transporters. However, little is known about the composition and regulation of the PIN protein complex. Here, using blue‐native PAGE and quantitative mass spectrometry, we identify native PIN core transport units as homo‐ and heteromers assembled from PIN1, PIN2, PIN3, PIN4 and PIN7 subunits only. Furthermore, we show that endogenous flavonols stabilize PIN dimers to regulate auxin efflux in the same way as does the auxin transport inhibitor 1‐naphthylphthalamic acid (NPA). This inhibitory mechanism is counteracted both by the natural auxin indole‐3‐acetic acid and by phosphomimetic amino acids introduced into the PIN1 cytoplasmic domain. Our results lend mechanistic insights into an endogenous control mechanism which regulates PIN function and opens the way for a deeper understanding of the protein environment and regulation of the polar auxin transport complex.</p><p class="para" id="N65541">Identification of native PIN‐FORMED (PIN) auxin transporter complexes in <i>Arabidopsis thaliana</i> shows formation of dimers that are stabilized by the auxin transport inhibitor NPA and natural flavonols.<div class="section"><div class="box" id="N65546"><div class="imageVideo"><img src="/dataresources/secured/content-1765744809254-b715faca-e7e5-4507-9316-dcb78451dcf1/assets/EMBJ-40-e104416-g012.jpg" alt=""/></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-13T00:00]]></pubDate>
        </item>
    </channel>
</rss>